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ABSTRACT 
 
Behavioral Effects of Inhibition of Cyclic Nucleotide  
Phosphodiesterase 2 (PDE2) in Mice 
 
Lindsay M Lueptow 
 
Cyclic nucleotide phosphodiesterases (PDEs) are a super-family of enzymes that 
regulate intracellular levels of the second messengers, cyclic AMP and cyclic GMP. 
Multiple PDEs have been shown to play vital roles in the central nervous system, with 
involvement in mood, reward mechanisms, and learning and memory. PDE2 is of 
special interest due to its high level of expression in forebrain regions, which are 
specifically implicated in mood and memory processes. In the first set of experiments, 
the potential role of PDE2 in depression- and anxiety-like behaviors was investigated 
using the forced swim test, tail suspension test, elevated plus maze, hole-board and 
step-through passive avoidance tests, as well as the object recognition test (ORT). The 
PDE2-selective inhibitor, Bay 60-7550 (3 mg/kg) did not significantly alter any of the 
depression- or anxiety-like behaviors, but did significantly enhance memory in the ORT. 
In the next set of experiments, the ORT was used to investigate the effect of PDE2 
inhibition on various stages of learning and memory. Bay 60-7550 was administered 30-
120 min prior to training, 0, 1, or 3 hrs after training, or 30 min prior to recall testing. 
Next, inhibitors of the cAMP or cGMP signaling pathways were administered 30 min 
prior to the PDE2 inhibitors Bay 60-7550 or ND7001, to assess the role cyclic nucleotide 
signaling on PDE2 inhibitor-enhanced memory. Finally, changes in the phosphorylation 
of CREB at Ser-133 and VASP at Ser-239 were determined to confirm activation of 
cAMP and cGMP signaling by PDE2 inhibition at behaviorally relevant doses. Bay 60-
7550 (3 mg/kg) significantly enhanced memory of mice in the ORT when given 30 min 
prior to training, immediately after training, or 30 min prior to recall. Inhibitors of the 
cGMP pathway blocked the memory-enhancing effects of both Bay 60-7550 (3 mg/kg) 
and ND7001 (3 mg/kg). Bay 60-7550 (3 mg/kg) significantly enhanced the 
phosphorylation of CREB and VASP, both targets of PKG. While PDE2 inhibition did not 
appear to play a major role in depression- and anxiety-like behaviors in these tests, 
future research will further elucidate the role of PDE2 in other mood-related behavior 
tests. Additionally, PDE2 does appear to play a major role in learning and memory, as 
seen in the ORT. Developing a greater understanding of the role of PDE-2 in these 
memory processes will allow for potential drug development for the intervention of a 
variety of human diseases related to cognitive decline and memory impairment, which 
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1.1 Cyclic Nucleotide Phosphodiesterases 
Over 6 decades ago, Earl Sutherland uncovered what we now understand to be 
one of the most important second messenger signaling systems in a cell, with the 
characterization of the synthesis of 3',5'-cyclic adenosine monophosphate (cAMP) via 
adenylyl cyclases and degradation via cyclic nucleotide phosphodiesterases (PDEs; 
Beavo and Brunton, 2002; Sutherland and Rall, 1958). Subsequently, a parallel "sister" 
system involving cyclic guanosine 3'5'- monophosphate (cGMP) was described (Ashman 
et al., 1963; Beavo and Brunton, 2002; Beavo et al., 1970). However, it wasn't until the 
1970s that the idea of targeting this "cyclic nucleotide system" for drug development was 
put forth (Amer, 1977; Ignarro et al., 1987; Keravis and Lugnier, 2012). Since then, 
researchers have discovered that this seemingly simple signaling pathway is incredibly 
diverse and complicated.  
The original discovery and characterization of cAMP was carried out in liver 
homogenates for the study of glycogen metabolism (Rall et al., 1956; Sutherland and 
Rall, 1958). Though Sutherland and colleagues discovered this second messenger 
system in a fairly narrow context, an incredible amount of research has since shown 
cAMP, and subsequently cGMP, to be expressed ubiquitously throughout the body, in 
every cell type, and involved in numerous signaling cascades. Additionally, as 
researchers have continued to parse the diversity of the cyclic nucleotide signaling 
cascades, they have also characterized another very important super-family of enzymes, 
which have proven to be invaluable regulators of cAMP and cGMP: the cyclic nucleotide 
phosphodiesterases (PDEs).  
 
3 
While cAMP and cGMP signaling can be controlled through regulation of their 
synthesis via adenylyl and guanylyl cyclases, once activated, inherent control over the 
spatial and temporal signal becomes very important. The PDE family, which serves as 
the off switch for these cyclic nucleotides, is encoded by 21 genes in humans and has 
over 100 splice variants that offer an incredible amount of diversity in terms of overall 
expression patterns, on/off mechanisms, post-translational modifications and subcellular 
targeting. As shown in Fig 1.1, the catalytic domains of all PDEs are relatively similar, but 
the N-terminal of each of the 11 PDE family members varies widely, with even further 
diversification amongst the splice variants. The PDEs are broadly grouped based on 
Figure 1.1 The PDE family. The conserved catalytic domain (shown in red) is located in the carboxy-
terminal portion of the phosphodiesterases (PDEs). The catalytic domain of PDE3 contains a unique 44-
amino-acid insert (shown in black). Many of the PDE families1, 2, 3 contain amino-terminal subdomains 
(such as GAF domains, transmembrane domains, targeting domains, upstream conserved regions 
(UCRs), PAS domains and REC domains) and N-terminal hydrophobic regions that are important in 
subcellular localization, in the incorporation of PDEs into compartmentalized signalosomes, in interactions 
with signaling molecules and molecular scaffolds, and in the regulation of PDE activity. GAF domains 
regulate the allosteric binding of cGMP (to PDE2, PDE5, PDE6 and PDE11), the allosteric binding of 
cAMP (to PDE10) and the regulation of catalytic activity (in PDE2, PDE5 and PDE6). Phosphorylation 
sites are labelled on the figure. CaMKII, calcium/calmodulin-dependent protein kinase II; ERK2, 
extracellular signal-regulated kinase 2; PKA, protein kinase A; Pat7, 7-residue nuclear localization signal. 
(Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery Maurice et al., 
2014 copyright 2014) 
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their ability to catalyze the hydrolysis of cAMP and/or cGMP. While PDEs 1, 2, 3, 10, and 
11 are able to hydrolyze and inactivate both cAMP and cGMP, PDEs 4, 7, 8 only 
hydrolyze cAMP, and PDEs 5, 6, 9 only hydrolyze cGMP. All of these factors contribute 
to the tight control of both cAMP and cGMP signaling.  
PDE expression patterns within the CNS are an important consideration when 
looking for potential targets for drug development. The relatively restricted expression of 
certain splice variants provides an opportunity for selective targeting of certain tissues or 
brain regions, thereby minimizing off-target effects seen with a more global approach. 
PDE expression in the CNS varies by splice variant, but general expression patterns are 
as follows: PDE1A is primarily in the hippocampus and cortex; PDE1B is primarily in the 
hippocampus and striatum; and PDE1C is exclusively expressed in the olfactory 
neuroepithelium (Lakics et al., 2010; Menniti et al., 2006); PDE2A is found primarily in 
cortex, hippocampus, amygdala, striatum, and medial habenula (Lakics et al., 2010; 
Stephenson et al., 2009; Van Staveren et al., 2003); PDE3 is expressed throughout the 
brain at very low levels; PDE4A is in the hippocampus, cortex olfactory bulb, striatum, 
thalamus, hypothalamus, amygdala, midbrain, and cerebellum, PDE4B & D are in the 
cortex, striatum, hypothalamus, midbrain, and cerebellum (Keravis and Lugnier, 2012; 
Lakics et al., 2010); PDE5A is expressed in the hippocampus, cortex, and cerebellum 
(Francis et al., 2011a; Keravis and Lugnier, 2012; Lakics et al., 2010); PDE6 is 
selectively expressed in the pineal gland and the rod and cone cells of the retina; PDE7A 
is expressed in the hippocampus, cortex, olfactory bulb, and striatum, while PDE7B is 
expressed in hippocampus, cortex, striatum and midbrain; PDE8B is expressed in 
hippocampus, cortex, olfactory bulb, striatum, and midbrain; PDE9A is in the 
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hippocampus, cortex, olfactory bulb, striatum, thalamus, hypothalamus, amygdala, 
midbrain, and cerebellum; and PDE10 is in the hippocampus, cortex, striatum, midbrain, 
and cerebellum; PDE11 has not been detected in brain (Keravis and Lugnier, 2012; 
Lakics et al., 2010; Menniti et al., 2006).  
Overall, there is a considerable amount of overlap in the expression patterns of 
individual PDE splice variants, not only within each brain region, but also on a subcellular 
level. While this may appear as redundancy within the systems, research has shown that 
each PDE splice variant provides distinct and important control over a select pool of 
cyclic nucleotides and can be dynamically regulated under different conditions (Francis 
et al., 2011b; Maurice et al., 2014). A broad example of this from Suvarna and O’Donnell 
shows that although PDE2 is able to hydrolyze both cAMP and cGMP, in primary rat 
cerebral cortex and hippocampus cultures, PDE4 is primarily involved in cAMP catalysis, 
while PDE2 is primarily involved in cGMP catalysis (Suvarna and O’Donnell, 2002). A 
more specific example of the dynamic regulation of PDE expression and function is seen 
with changes in the subcellular expression of PDE1. In an injury model of vascular 
smooth muscle cells, during the uninjured, quiescent phase, PDE1 is primarily found in 
the cytosol, while during the injured, proliferation phase, PDE1 is primarily found the 
nucleus (Nagel et al., 2006). These are only two examples the dynamic range of PDEs, 
and the importance of developing a thorough understanding of the most basic role of 
each PDE splice variant in physiological and behavioral processes, in hopes of the 





1.2 Clinical Relevance of Phosphodiesterase Inhibitors for 
CNS Dysfunction 
The development of more selective PDE inhibitors, as well as more targeted 
genetic tools, has provided a greater understanding of the role of individual PDE splice 
variants in specific biological processes and has renewed interest in PDEs as potential 
novel therapeutic drug targets. Currently, the only PDE inhibitors with FDA approval for 
clinical use target PDE3, PDE4 and PDE5 (Table 1.1). The PDE5 inhibitor sildenafil 
(Viagra; Pfizer) was originally investigated in clinical trials for the potential treatment of 
angina and coronary artery disease. While there were no robust effects for either 
Generic name  
(Brand name; original company) 
PDE 
Targeted 





(Pletal; Otsuka Pharmaceutical) 




PDE3 Refractory heart failure 1987 
Apremilast  
(Otezla; Celgene) 





Chronic obstructive pulmonary 




PDE5 Erectile dysfunction 2012 
Sildenafil  
(Viagra; Pfizer) 


















PDE5 Erectile dysfunction 2003 
Table 1.1 FDA approved PDE inhibitors for clinical application 
 
7 
disease, reports of efficacy for erectile dysfunction launched sildenafil, and subsequent  
PDE5 inhibitors, into popular use. Subsequently, because of the fairly high expression of 
PDE5 in vascular smooth muscle, PDE5 inhibitors have shown efficacy in the treatment 
of pulmonary arterial hypertension (Maurice et al., 2014). Early generation PDE4  
Inhibitors, including rolipram, showed great promise in the treatment of plaque psoriasis  
and inflammatory diseases, as well as depression; however, clinical application was 
halted due to unpleasant side effects including nausea and vomiting (Maurice et al., 
2014). The new generation of PDE4 inhibitors has been designed to mitigate these side 
effects, and both apremilast and roflumilast are now FDA approved for both psoriatic 
arthritis and COPD with chronic bronchitis (Table 1.1). 
Despite the relatively limited number of PDE inhibitors with FDA approval, there 
are over 20 novel PDE inhibitor compounds, either discovered or newly synthesized, in 
various stages of clinical trials, targeting numerous disease (for a full list as of 2014, see 
Maurice et al., 2014). For example, resveratrol, a polyphenol found in red wine, is a pan-
PDE inhibitor that has shown promising results in animal models for the treatment of 
glucose intolerance and Alzheimer’s disease and is now in Phase II clinical trials for 
both. While resveratrol does have numerous putative targets, the main therapeutic 
actions are thought to be mediated via PDE4 (Maurice et al., 2014; Park et al., 2012). 
Many of the previously approved PDE3, 4 and 5 inhibitors are also undergoing clinical 
trials for potential efficacy in other diseases, including PDE3 inhibitor cilostazol for 
fertility, dementia, and ischemic stroke, PDE4 inhibitor apremilast for acne, and PDE5 
inhibitors sildenafil and tadalafil for diabetes and other endocrine functions, muscular 
dystrophy, schizophrenia, and heart failure (Maurice et al., 2014).  
 
8 
Though these compounds have been used with varying degrees of success, all of 
the currently FDA approved PDE inhibitors are non-selective in regards to subtypes 
within their enzyme family and have some off-target effects for other family members, 
which often results in a narrow therapeutic range, as well as severe side effects and 
toxicities. Many PDE inhibitors have failed clinical trials for these reasons. Rolipram was 
a very promising PDE4 inhibitor developed in the 90s, with robust antidepressant-like 
effects in preclinical studies (Maurice et al., 2014). However, despite its efficacy in some 
clinical trials, it has not advanced to approval due to dose-limiting side effects of nausea 
and emesis.  These effects have been suggested to be mediated by the PDE4D subtype, 
which is highly expressed in the area postrema, an emetic trigger site (Maurice et al., 
2014). Because of this, researchers have been working to develop drugs with an 
alternate mechanism of action or isoform selective inhibitors to increase the safety profile 
and efficacy. PDE4 inhibitors, specifically, have been redesigned to act as allosteric 
modulators at specific splice variants, and have resulted in significantly fewer 
gastrointestinal side effects, allowing for higher doses and a safer therapeutic range 
(Burgin et al., 2010).  
1.3 Biology and Current Treatments for Mood and Cognitive 
Disorders 
It is because of the high level of expression of certain PDEs, such as PDE2 and 4, 
in limbic and cortical regions of the brain that PDE inhibitors have generated much 
interest for the treatment of neuropsychiatric disorders such as depression, anxiety, as 
well as disorders affecting learning and memory (Beavo and Brunton, 2002; Bolger et al., 
1994; Francis et al., 2011b; Menniti et al., 2006; Xu et al., 2011). Anxiety and depression 
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are two of the most prominent mood disorders reported in the United States and 
worldwide each year (Kessler et al., 2005; Norquist, 1998; Services, 2009) and the 
incidences of cognitive impairment, ranging from mild cognitive decline, to late stage 
dementia and Alzheimer’s disease, are reaching all-time highs with an aging baby 
boomer population (Hebert et al., 2003). Current treatment options are limited, often 
falling short of full clinical relief and/or resulting in unpleasant or intolerable side effects. 
This raises a great need for a deeper, more complete understanding of the etiology and 
biology of mood and cognitive disorders, for identification of novel drug targets for safer, 
more efficacious treatment options.  
1.3.1 Biology of Anxiety and Depression 
According to the DSM-V, generalized anxiety disorder is classified by excessive 
anxiety and worries occurring most days over a 6 month period, and is difficult for an 
individual to control (American Psychiatric Association, 2013). Additional symptoms may 
include:  restlessness or feeling on edge, fatigue, irritability, difficulty concentrating, 
muscle tension, or sleep disturbances. Depression is classified by an impaired mood or 
loss of interest in daily activities for at least 2 weeks, with impaired social, occupational 
or educational function. Additional symptoms may include: feeling irritable, significant 
weight gain/loss, insomnia/hypersomnia, psychomotor agitation or retardation, loss of 
energy, feelings of worthlessness, difficulty concentrating, or suicidal ideation (American 
Psychiatric Association, 2013). Symptoms experienced among patients may vary widely, 
making diagnosis and treatment difficult and often requiring multiple approaches before a 
full therapeutic effect is possible. Part of the lack of successful treatment options stems 
from the limited understanding of not only the etiology of anxiety and depression, but 
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also, a very limited understanding for how current treatment options result in a 
therapeutic effect.  
Currently, researchers have identified a few key brain regions involved in anxiety 
and anxiety-like behaviors. Imaging researchers have identified a "fear circuitry" within 
the human limbic system of the brain, which includes the amygdala, hippocampus, 
anterior cingulate cortex, and insula, which are hyperactive during anxiety provoking 
situations (Engel et al., 2009; Holzschneider and Mulert, 2011; Kheirbek et al., 2013; Tye 
et al., 2011). Many of these brain regions, including the hippocampus and amygdala, are 
conserved in the mouse brain and have also been implicated in anxiogenic-like 
behaviors in mice (see Fig 1.2). More specifically, the ventral hippocampus has been 
implicated in anxiety 
behaviors in mice, and its 
function is correlated with 
activity in the medial 
prefrontal cortex (mPFC; 
Adhikari et al., 2010; 
Deacon and Rawlins, 2005; 
Engin and Treit, 2007). The 
amygdala, which has 
classically been considered 
the epicenter of fear and 
anxiety, has numerous 
inputs and targets, some 
Figure 1.2 The human brain and the mouse brain. As well as having a 
mass of about 2,700 times greater than that of the mouse brain (right), it 
is the convoluted folds of an extensive cerebral cortex that distinguish 
the human brain (left) from the brains of lower species, such as the 
mouse. The potential functional significance of these species differences 
to emotional regulation and the implications for modelling emotional 
states in mice is yet to be fully under - stood. However, it is clear that 
many brain structures involved in limbic regulation of emotion, such as 
the hippocampus and amygdala, are evolutionarily conserved from 
mouse to man.  
(Reprinted by permission from Macmillan Publishers Ltd: Nature 
Reviews Drug Discovery, Cryan and Holmes, 2005 copyright 2005) 
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reciprocating, including glutamatergic output to the bed nucleus of the stria terminalis 
(BNST), nucleus accumbens (NAc), hippocampus and cortex, with concurrent 
GABAergic output from the central-medial nucleus of the amygdala to many of the same 
brain regions (Engin and Treit, 2007; Etkin, 2012; Holzschneider and Mulert, 2011; 
Petrovich et al., 2001; Tye et al., 2011). These complicated signaling connections only 
suggest a role in the etiology and regulation of anxiety-like behavior. Further research is 
required to truly understand the functional role of these brain regions in both the onset 
and treatment of anxiety disorders.   
 These same brain regions have also been implicated in depressive behaviors in 
both humans and rodents. Though, because patients suffering from depression present 
with a wide variety of different and often contradictory symptoms, the underlying 
biological and physiological processes of depression are likely complex and 
heterogeneous. Postmortem studies have attempted to identify pathological anomalies, 
and have shown decreased neuronal size, a decreased glial population, and shorter 
dendrites in cortical and hippocampal regions (Hercher et al., 2009; Karege et al., 2005; 
Krishnan and Nestler, 2010). Imaging techniques have shown decreased volume in 
these same brain regions, as well as hypermetabolism in the subgenual cingulate cortex 
and amygdala, as well as hypometabolism in the dorsal prefrontal cortex and striatal 
regions (Krishnan and Nestler, 2010; Videbech and Ravnkilde, 2004). However, 
correlating any of these biological changes with behavior changes has been difficult, and 
despite the wealth of available research, definite conclusions regarding the etiology of 





1.3.2 Current Limitations of Pharmacological Treatments for Anxiety and Depression 
 Part of the interest in developing novel therapeutics for the treatment of a variety 
of CNS diseases stems from the unfortunate reality that currently available 
pharmaceuticals have limited efficacy, side-effects, and in some cases, abuse liability. 
Currently, the first-line treatment for anxiety and depression are antidepressants. 
Selective serotonin reuptake inhibitors (SSRIs) are one of the most commonly used, 
second-generation antidepressants that work by blocking the reuptake of serotonin 
(5HT) in the synaptic cleft. While all classes of antidepressants have shown some 
efficacy in treating depression and anxiety disorders, SSRIs have shown reliable efficacy 
and tolerability (Linden et al., 2012). Venlafaxine and other serotonin and norepinephrine 
reuptake inhibitors (SNRIs) are also frequently used for the treatment of depression and 
anxiety. As with the SSRIs, SNRIs are well tolerated and are safe to use in higher risk 
populations, such as children or the elderly (Koen and Stein, 2011; Ravindran and Stein, 
2010; Shelton, 2004). Antidepressants, however, take weeks to months of repeated use 
before the onset of a therapeutic effect, and they also carry undesired side effects such 
as weight gain, somnolence, and agitation, which can be counter indicative for treating 
anxiety and depression (Reinhold et al., 2011).  
Benzodiazepines are another option for the treatment of anxiety disorders. While 
these were once considered a first-line treatment, their safety profile is somewhat more 
limited, and the side effects, including drowsiness and decreased alertness, can be 
impairing (Ravindran and Stein, 2010; Reinhold et al., 2011). Additionally, their maximal 
efficacy is only seen with short duration treatments of less than 4 weeks, as patients can 
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develop tolerance and dependence with prolonged use. Antidepressants do not lead to 
tolerance, and can be safely discontinued with proper tapering.   
 For anxiety, and certain cases of depression, less widely used treatments include 
atypical antidepressants, bupropion (norepinephrine and dopamine reuptake inhibitor), 
nonbenzodiazepine anticonvulsants, atypical antipsychotics, and busiprone (5-HT1A 
receptor partial agonist) (Gorman, 2003; Linden et al., 2012; Ravindran and Stein, 2010; 
Reinhold et al., 2011; Rudolph and Knoflach, 2011). These classes of drugs are 
generally not considered until the first line of treatment has shown to be ineffective or not 
well tolerated. Many of these classes have the same disadvantages as the first lines of 
treatment, including limited or delayed efficacy, side effects, and poor tolerability in 
certain vulnerable populations (Hettema, 2008; Koen and Stein, 2011; Lenze and 
Wetherell, 2011; Ravindran and Stein, 2010; Reinhold et al., 2011). 
 Older generations of antidepressants may also be used for first-line treatment-
resistant cases of anxiety and/or depression. Tri- and tetra-cyclic antidepressants (TCAs) 
were the first-generation of reuptake inhibitors, originally synthesized in the late1950s 
(Kuhn, 1958; Ravindran and Stein, 2010). While TCAs do show efficacy for both anxiety 
disorders and depression, their clinical use is discouraged  due to significant 
anticholinergic and antiadrenergic side effects, including dry mouth, constipation, 
palpitations, orthostatic hypotension, and risk of toxicity in overdose (Schatzberg et al., 
2007). The very first antidepressant was the monoamine oxidase inhibitor (MAOI) 
iproniazid, which was originally used to treat tuberculosis (Lopez-Munoz and Alamo, 
2009). While it was found to have limited efficacy for its intended purpose, patients 
reported elevated mood, and it was subsequently found to increase norepinephrine (NE) 
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and 5HT levels in the brain (Schildkraut, 1965). This led to the synthesis of additional 
MAOIs. However, they are now considered a third-line treatment option for both 
depression and anxiety due to undesirable side effects and the potential for a 
hypertensive crisis due to interaction with certain foods and drugs (Schatzberg et al., 
2007). While they lack the anticholinergic effects seen with TCAs, they do cause 
orthostatic hypotension, insomnia at night, and sedation during the day (Schatzberg et 
al., 2007).  
1.3.3 Biology of Learning and Memory & Cognitive Dysfunction 
Cognitive dysfunction is a hallmark of numerous psychiatric illnesses, with the 
most common being mild cognitive impairment (MCI), with or without turnover to 
Alzheimer’s Disease (AD), and Parkinson’s Disease (PD). MCI is defined as cognitive 
capacity below what is expected from a normal person that age and affects 
approximately 10-25% of individuals over the age of 70 (Kumar et al., 2015; Różyk-
Myrta, 2015). There is a turnover rate of approximately 10% per year from MCI to full 
dementia, including AD (Różyk-Myrta, 2015). Alzheimer’s disease currently affects over 
4.5 million Americans and had a global economic impact of $605 billion in 2010 alone 
(Kumar et al., 2015; Różyk-Myrta, 2015). By the year 2050 it is estimated that 1 in 85 
people globally will suffer from AD (Dzirasa et al., 2010). Concurrently, while motor 
dysfunction is the classical symptom of PD, dementia is often overlooked, despite 
affecting approximately three-fourths of patients with PD (Aarsland et al., 2003; Hely et 
al., 2008). The statistics for any one of these forms of cognitive impairment alone are 
cause for concern. Taken together, the need for a greater understanding of cognitive 
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processing (and therefore cognitive impairment) and potential treatments is more than 
critical. 
Interestingly, cognitive processing is done by many of the same brain regions 
discussed above (see section 1.3.1). One of the main brain regions repeatedly 
implicated in the formation of new memories is the hippocampus and surrounding 
structures, or the para-hippocampal region (PHR), which includes the subiculum and 
rhinal cortical areas (Strien et al., 2009). The complex interplay among these various 
subregions is responsible for the bulk of learning, including acquisition and consolidation, 
as well as for memory retrieval.  
The underlying biological processes of different forms of memory can vary greatly, 
but the main phases of learning and memory can be grouped into three broad 
categories: memory acquisition, consolidation (early and late phases), and recall 
(Kandel, 2012; Mayr and Montminy, 2001; Muller, 2012; Wang et al., 2006). From here, 
there are many ways to classify learning and memory based on task (i.e., spatial 
memory vs object memory), duration of memory (i.e., short term vs long term memory; 
STM & LTM, respectively), as well as the manner of memory acquisition (i.e., explicit vs 
implicit memory) (Kandel, 2012; Muller, 2012; Wang et al., 2006; Winters et al., 2010). 
Because the underlying biological processes of these different forms memory can vary 
greatly (despite utilizing similar brain regions), the following will focus on one form of 
memory, object recognition memory.  
Object recognition memory is considered a crucial component of one’s ability to 
successfully survive and navigate a very complex world. Object recognition memory is a 
key component of human declarative memory, which is defined as the conscious 
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memory for facts and events, and is one of the first, and most severely affected forms of 
memory by various diseases that lead to cognitive impairment, such as PD or AD 
(Desgranges, 1998; Gabrieli et al., 1995; Golby et al., 2005). Various object recognition 
tests have been used across species to develop a greater understanding of biology of 
recognition memory, and therefore, aspects of declarative memory, in hopes of 
identifying novel drug targets for the treatment of various forms of declarative memory 
loss (Akkerman et al., 2012; Winters et al., 2010, 2008).  
Our current understanding of the neuroanatomical correlates of object recognition 
memory stems mainly from ablation studies. For both rodents, non-human primates, and 
humans, the putative brain regions responsible for object recognition memory are the 
rhinal cortical areas, including the perirhinal and entorhinal cortices, as well as the 
remaining PHR (Antunes and Biala, 2012; Balderas et al., 2013; Brown et al., 2012; 
Clark and Squire, 2010; Dere et al., 2007; Jobim et al., 2012; Seoane et al., 2012; 
Suzuki, 1996; Wan et al., 1999; Warburton and Brown, 2010; Weible et al., 2012; 
Winters and Bussey, 2005; Winters et al., 2010, 2008). Many lesion studies for both non-
human primates and rodents repeatedly demonstrate the importance of the entorhinal 
and perirhinal cortical areas, specifically in object recognition memory tasks (Balderas et 
al., 2013; Brown et al., 2012; Dere et al., 2007; Wan et al., 1999; Warburton and Brown, 
2010; Winters et al., 2008), while evidence for the necessity of hippocampal regions 
remains somewhat mixed (Brown et al., 2012; Stupien et al., 2003; Wan et al., 1999; 
Warburton and Brown, 2010). However, one likely source of inconsistency stems from 
the apparatus and testing conditions used, as these tend to vary greatly between 
research groups. Those that make use of more spatially-cued arenas are possibly 
 
17 
shifting the cognitive task from one that is purely object-related to one that is more 
spatially-related, and the hippocampus is required for spatial memory tasks (Warburton 
and Brown, 2010).  
Additionally, meta-analysis of lesion studies in monkeys shows that, while there is 
a positive correlation between the size of perirhinal lesion and recognition memory 
impairment, a negative correlation is found between the size of the hippocampal lesion 
and recognition memory impairment (Baxter and Murray, 2001). This means that the 
smaller the lesion in the hippocampus, the greater the memory impairment. While there 
is no definitive answer to why or how this inverse relationship exists, the authors suggest 
that the hippocampus has competing processes for recognition memory, and a small 
lesion leads to disruption of these competitive processes, leading to overall inhibition, 
whereas a larger lesion would fully prevent any competitive inhibition from the 
hippocampus (Baxter and Murray, 2001). Other analysis of similar studies failed to find 
this inverse relationship between hippocampal lesion size and argued that testing 
conditions, rather than lesion size, contributed to study performance (Zola and Squire, 
2001). They suggest that perhaps there is a positive correlation size with hippocampal 
lesion and memory deficit up until the lesion is able to fully disable the structure, which, 
according to their analysis, may only be around 20% damage (Zola and Squire, 2001). 
This means any further damage would not increase the memory deficit. Nonetheless, no 
matter how large the lesion in the hippocampus, lesions to the perirhinal cortex always 
resulted in larger recognition memory deficits (Baxter and Murray, 2001; Warburton and 
Brown, 2010; Zola and Squire, 2001).  
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In the context of cognitive decline, the brain regions most profoundly affected by 
MCI and dementia in AD and PD are fairly similar. The first and most severely affected 
brain region in AD is the medial temporal lobe, which encompasses the amygdala, 
hippocampus, and the entire PHR (Desgranges, 1998; Golby et al., 2005; Ossenkoppele 
et al., 2015). While the primary locus of PD has always been considered the substantia 
nigra, recent studies show widespread cortical thinning in medial temporal cortical areas 
in patients with PD, and further thinning in patients with PD that suffer from dementia 
(Aarsland et al., 2003; Hely et al., 2008; Mak et al., 2015). As previously mentioned, 
these are the very regions of the brain necessary for learning and memory processing. 
Early damage to these structures profoundly affects declarative memory processing, 
which is what is seen across these various cognitive diseases (Aarsland et al., 2003; 
Goldman and Weintraub, 2015; Hampstead et al., 2015; Mak et al., 2015; Ossenkoppele 
et al., 2015).   
1.3.4 Current Limitations of Pharmacological Treatments for Cognitive Dysfunction 
 Like our current understanding of cognitive disorders, treatment options are 
extremely limited. The first FDA approved drug for the treatment of AD was an 
acetylcholinesterase inhibitor (ACheI), tacrine (Cognex), which was discontinued in 2013 
due to safety concerns. Currently approved treatments for AD include three ACheIs, 
donepezil (Aricept; Esai, Tokyo, Japan), galantamine (Razadyne; Janssen Research 
Foundation), and rivastigmine (Excelon; Novartis), as well as one n-methyl-d-aspartate 
receptor (NMDAR) antagonist, memantine (Namenda; Forest Laboratories) and one 
combination ACheI/NMDAR antagonist (donepezil and memantine; Namzaric; Forest 
Laboratories) (Goldman and Weintraub, 2015; Kumar et al., 2015; Rafii and Aisen, 
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2015). Currently, only one drug has FDA approval for the treatment of dementia in PD, 
and that is the ACheI rivastigmine (Goldman and Weintraub, 2015).  
 The primary and most obvious drawback of all of these drugs is the fact that they 
are mere symptom stop-gaps, and are not able to reverse or stop disease progression. 
Additionally, because our current understanding of many of these cognitive diseases lies 
only in the actual disease processes and not their etiology, the mechanism of drug action 
for most of these disorders, including AD and PD, addresses dementia only after 
substantial neuronal loss has occurred. This means that drugs such as ACheIs only 
attempt to restore what has already been lost in terms of boosting neuronal signaling, 
and are unable to stop or reverse the neuronal loss that has already occurred. Therefore, 
it is vital to gain a deeper understanding of cognitive processing on a basic level, and 
subsequently in a disease state, to gain a thorough understanding of the etiology of 
cognitive disorders and identify appropriate targets for drug development to stop and/or 
reverse these debilitating conditions.    
1.4  Role of PDE2 in CNS Function 
While almost all of the PDEs have been found to have some level of expression in 
the brain, PDE2 has exceptionally high levels in frontal cortical regions, the 
hippocampus, and the amygdala, brain regions responsible for mood and cognition 
(Table 1.2; Bolger et al., 1994; Deng et al., 2007; Gomez and Breitenbucher, 2013; 
Stephenson et al., 2009). Though there is much to understand regarding the role of 
PDE2 in behavior, researchers have demonstrated a role of PDE2 in both mood and 
cognition. Research has primarily utilized pharmacologic tools, as the constitutive PDE2 
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knockout is embryonic lethal (Stephenson et al., 2009). While a conditional knockout is in 
development, no work has been published regarding a genetic knockout of PDE2.  
 In terms of drug development, PDE2 is of particular interest due to its high 
expression in cortical and limbic regions of the brain, which are responsible for the 
regulation of mood and cognition. This interest is 2-fold. Firstly, as selective inhibitors for 
PDE2 have only been developed in the last decade, the current understanding of the 
basic biological role of PDE2 in rodent behavior is fairly limited. Secondly, PDE2 is a 
potential drug target for the treatment of mood and/or cognitive disorders, based on its 
pattern of expression in the brain. Therefore, researchers are interested in not only 
developing a deeper understanding of PDE2 in behavior, but also targeting PDE2 for 
potential drug development for a variety of diseases. 
PDE2 was first identified in a rat liver by Beavo, Hardman and Sutherland in 1971 
(Beavo et al., 1970). Three different splice variants of mammalian PDE2 are encoded by 
a single gene (PDE2A) and differ only in their N-terminal, which determines intracellular 
Peripheral Expression CNS Expression 
Endothelial Cells: Hippocampus (+++) 
Stomach (+) 
Small/Large Intestines (+) 
Vasculature (+) 
Frontal Cortex (++) 
Amygdala (++) 
Striatum (++) 
Heart/Lung (+) Medial Habenula (+++) 
Adrenal Cortex (+++) 
(aldosterone secretion) 
Little to no detectable expression in mid or hind 
brain 
Table 1.2 Expression of PDE2 in peripheral and CNS tissue. + = low expression, ++ = moderate expression, 
+++ = high expression 
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localization to either the membrane (PDE2A2 and PDE2A3) or the soluble fraction 
(PDE2A1). PDE2A2 was originally cloned from rat brain cDNA (Repaske et al., 1992; 
Yang et al., 1994), while PDE2A1 and 2A3 were cloned from bovine heart cDNA 
(Sonnenburg et al., 1991; Tanaka et al., 1991). An identical PDE2A3 variant was also 
cloned from human brain tissue (Rosman et al., 1997). Expression of a similar GAF-
containing PDE2, PDE2B, is found in the parasite Trypanosoma brucei, but has yet to 
show significant cGMP activity (Laxman et al., 2005; Rascón et al., 2002).  
The first and, as of now, only commercially available PDE2-selective inhibitor was 
patented in 2003 by Bayer (Niewohner et al., 2003). Unfortunately, the compound, Bay 
60-7550 has solubility issues and has limited ability for crossing the blood brain barrier 
(BBB). Nonetheless, the synthesis of Bay 60-7550 has allowed researchers to move 
forward in developing a better understanding of the role of PDE2 in rodent behavior. 
Since then, a few additional compounds have been synthesized, including ND7001 
patented in the US in 2008, and very recently Lu AF64280 (Abarghaz et al., 2005; 
Redrobe et al., 2014). However, behavioral research has relied on only 2 compounds, 
Bay 60-7550 and ND7001, for our current understanding of PDE2 in mood and cognition. 
While the current literature shows a promising role for PDE2 as a potential therapeutic 
drug target, much more research is needed to fully understand PDE2 and its signaling 
partners in both mood and cognition. 
1.4.1 PDE2 in Anxiety and Depression  
 The O’Donnell group first looked at the possible role of PDE2 in the reversal of 
stress-induced anxiety- and depression-like behaviors in mice. Using Bay 60-7550, they 
showed PDE2 inhibition could block oxidative stress induced by the chemical L-
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buthionine-(S,R)-sulfoximine (BSO) in mice (Masood et al., 2008; Niewohner et al., 
2003). Firstly, they were able to show that BSO did, in fact, induce oxidative stress in 
neurons, and also resulted in anxiety-like behaviors in mice in the elevated plus maze 
(EPM) and hole board test (HB), both reliable screens for anxiety-like behavior. Pre-
treatment with Bay 60-7550 was able to prevent both BSO-induced cellular oxidative 
stress and anxiety-like behavior (Masood et al., 2008).     
 From here, the O’Donnell group moved on to explore the role of PDE2 inhibition in 
various other models of stress-induced anxiety and depression, including acute restraint 
stress (Masood et al., 2009) and chronic unpredictable stress (Ding et al., 2014; Xu et 
al., 2015, 2013). The findings consistently point to a role of PDE2 inhibitors, both Bay 60-
7550 and a second selective inhibitor ND7001, in preventing stress-induced changes on 
a cellular and behavioral level. More specifically, restraint stress and/or chronic 
unpredictable stress leads to increases in depression- and anxiety-like behavior in the 
TST and FST (Ding et al., 2014) and EPM and HB (Ding et al., 2014; Masood et al., 
2009), respectively, decreases in cognitive function in the MWM and ORT (Xu et al., 
2015), as well as decreases in neuronal spine density and altered spine morphology (Xu 
et al., 2015). All of these stress-induced changes were blocked by inhibitors of PDE2. 
Additionally, it was consistently demonstrated that the protective effects of PDE2 
inhibition were mediated via the NOS/cGMP/PKG pathway rather than the cAMP/PKA 
pathway (Masood et al., 2009, 2008; Xu et al., 2015, 2013). These results demonstrate 
that PDE2 inhibition plays a role in stress-induced anxiety and depression, and suggest 




1.4.2 PDE2 in Learning and Memory 
 The potential for PDE2 inhibition in cognitive enhancement was first shown by 
Boess and colleagues in 2004. They demonstrated that Bay 60-7550 significantly 
enhanced long-term memory in both the ORT and social recognition tests (Boess et al., 
2004). From there, researchers showed that the memory enhancing effects of PDE2 
inhibition were time-dependent, and only seen when Bay 60-7550 was given either 
immediately after training or 3 hrs after training, but not when given 1 hr or 6 hrs after 
training (Bollen et al., 2014; Rutten et al., 2007). Interestingly, these effects were 
differentially mediated by cAMP and cGMP signaling pathways. A PKG inhibitor was able 
block the memory-enhancing effects of PDE2 inhibition when Bay 60-7550 was given 
immediately after training, but not 3 hrs after training. Alternatively, a PKA inhibitor was 
able to block the memory-enhancing effects of PDE2 inhibition when Bay 60-7550 was 
given 3 hrs after training, but not immediately after training (Bollen et al., 2014). 
Interestingly, this suggests a time-dependent role for both cAMP and cGMP in PDE2-
mediated memory enhancement. This differs from previous literature involving the 
protective effects of PDE2 inhibition from stress-induced changes in anxiety and 
depression, which show cGMP/PKG primarily, and solely, mediates the effects (Masood 
et al., 2009, 2008; Xu et al., 2015, 2013). 
 Additional studies show PDE2 inhibition to be protective against various rodent 
models of cognitive impairment. The NMDAR antagonist MK-801 and the muscarinic 
acetylcholine receptor antagonist scopolamine both are shown to impair memory in the 
ORT. Bay 60-7550, given with either MK-801 or scopolamine 30 min prior to training, 
significantly prevents the drug-induced memory deficits (Reneerkens et al., 2013b). Bay 
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60-7550 also prevented PCP-induced memory deficits in an extradimensional-
intradimensional (ED/ID) task of cognitive flexibility in rats (Rodefer et al., 2012), and 
prevented cognitive impairment in the ORT following tryptophan depletion (van 
Donkelaar et al., 2008). In a mouse-model of AD, chronic Bay 60-7550 ameliorated 
deficits in the object location test, a variant of ORT that focuses on spatial memory over 
object recognition (Sierksma et al., 2012). One newly synthesized selective PDE2 
inhibitor, Lu AF64280, was also protective against PCP-induced memory deficits in both 
the ORT and ED/ID cognitive task (Redrobe et al., 2014). These results suggest a role 
for PDE2 inhibition in cognitive enhancement in both normal and challenged systems. 
1.5 Testing Mood and Cognition in Mice 
Rodents provide a relatively easy and effective means for assessing potential 
clinical relevance of novel drug compounds whose safety and efficacy in a human 
population are unknown. While researchers cannot directly assess the “depression” or 
“anxiety” levels in mice, there are many behavioral tests available for analysis of certain 
domains of these disorders that are considered to be depression- or anxiety-like. Most of 
these tests do not actually mimic depression or anxiety, and are therefore not considered 
models of either, but instead, many of these tests have shown high predictive validity for 
efficacy of a compound in a human population, and are therefore considered screens for 
antidepressant or anxiolytic activity. While there are currently no models or screens that 
can mimic or test all domains of anxiety or depression, each test offers various pros and 
cons for different aspects of each. However, because of this, interpretation of findings in 
these tests must be carefully considered.  
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Testing changes in learning and memory in rodents is somewhat less ambiguous. 
However, because rodents have a limited cognitive capacity, and, of course, lack certain 
brain structures necessary for higher cognitive function, these tests also tend to focus on 
one aspect or domain of memory, such as spatial memory, and again, interpretation of 
results should be carefully considered, as changes in one domain of rodent memory may 
not translate into changes in a more complex species, such as humans. 
Though these drawbacks may make it difficult to fully understand the etiology of 
complex human diseases, carefully designed and controlled experiments of rodent 
behavior offer a more simplified system to begin to understand the basic mechanisms of 
more complex behaviors. Many of the most commonly used rodent behavioral tests 
exploit stereotyped or innate tendencies of mice and rats to detect changes or 
aberrations following an experimental manipulation, such as a drug administration or a 
genetic alteration. Because these simple behaviors are easily observed, any changes or 
deviations indicate that the experimental manipulation is having an effect. Quantifying 
these changes not only allows researchers to gain a better understanding of  an 
unknown molecule or signaling pathway of interest in regards to behavior, but also 
allows for the identification of novel drug targets for the development of faster acting, 
more efficacious therapeutics with fewer side effects. The following highlights some of 
the most commonly used tests for anxiety- and depression-like behaviors, as well as 
tests for learning and memory. 
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1.5.1 Tests for anxiety-like behaviors in mice 
Numerous behavioral assays exist for 
testing anxiety-like behaviors in mice. Each 
test exploits slightly different behaviors in 
rodents, which must be considered when 
analyzing results in different rodent strains. 
Most anxiety-related tests place mice in a 
somewhat stress-inducing environment to 
elicit avoidance or resilient behaviors. The 
following highlights the most frequently used 
test for anxiety-like behaviors in mice. 
First introduced in the mid-80s, the 
EPM is among the most commonly used 
tests for anxiety-like behavior in mice (Haller 
and Alicki, 2012; Handley and Mithani, 1984; 
Pellow et al., 1985). The EPM consists of an 
elevated apparatus with 2 closed arms and 2 
open arms (Fig 1.3a). The amount of time 
spent in each arm, as well as the number of entries into each arm is quantified. This test 
exploits a balance between two different behaviors in mice: their preference for a closed, 
darker environment (i.e., the closed arms) and their innate exploratory or novelty-seeking 
behavior, which compels them onto the open, more exposed areas (i.e., the open arms). 
Anxiety-like behavior would be indicated by a decrease in the amount of time and entries 
Figure 1.3. Tests for anxiety-like behaviors in 
mice. a, the EPM consist of 2 open arms and 2 
closed arms. The mouse is placed in the center and 
allowed to explore. Time in the open arms is used 
as a measure of anxiety-like behavior. b, In the open 
field test, mice are placed in the center and allowed 
to explore. Time spent in the center is used as a 






into the open arms relative to control. Anxiolytic-like behavior would be indicated by an 
increase in the amount of time and entries into the open arms relative to control. This 
test has high predictive validity for anxiolytic drugs in humans and is commonly used as 
a screen for potential novel anxiolytics.  
The HB test exploits somewhat similar behaviors in mice. This test consists of a 
board with small holes drilled in the center regions. The time the rodent spends dipping 
its head into the hole and the number of dips is quantified. The more time dipping and 
the greater number of dips is indicative of anxiolytic-like behavior (Boissier and Simon, 
1964, 1962; Takeda et al., 1998). This test is sensitive to known anxiolytic agents and to 
stress-inducing anxiogenic behavior (Takeda et al., 1998).  
A third frequently used measure of anxiolytic behavior is the open field test. This 
again places the mouse in a somewhat stressful environment, consisting of an open 
field, brightly illuminated in the center. Mice are allowed to explore for 5 minutes, and the 
amount of time spent in the center area is quantified (Fig 1.3b). The more time spent in 
the center area is indicative of anxiolytic-like response (Cryan and Holmes, 2005). One 
benefit of this test is that center time can be quantified for the first five minutes of a 
longer run to quantify overall locomotor behavior. This allows proper analysis of both 
overall locomotor changes between treatments and potential anxiolytic properties.  
1.5.2 Tests for depression-like behaviors in mice 
Testing depression-like behaviors in mice is somewhat more difficult due to the 
heterogeneity of the disease in humans. One of the most commonly used tests for 
depression-like behaviors is the forced swim test (FST), which was described by Porsolt 
in 1977 (Porsolt, 1977). This test consists of placing a rodent in a cylinder of water and 
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timing 3 main behaviors: immobility, swimming, and climbing (Fig 1.4a). Immobility is 
defined as the minimum movement required keeping the head above water. Swimming is 
active movement through the water, and climbing is attempting to escape up the wall of 
the cylinder. After a period of attempted escape, which consists of swimming and 
climbing, rodents will enter a period of immobility in which they “give up”, sometimes 
referred to as behavioral despair. Increases in immobility time are indicative of increased 
depression-like behavior, while a decrease in immobility is indicative of decreased 
depression-like behavior, as compared to controls. The FST is sensitive to standard 
antidepressant treatments 
and is used as a screen for 
antidepressant efficacy of 
novel putative 
antidepressants.  
The tail suspension 
test (TST) is similar to the 
FST in that it also measures 
immobility time and is considered to be an indication of behavioral despair (Steru et al., 
1985). Mice are suspended from a bar by their tail and immobility time is quantified (Fig 
1.4b). As with the FST, the mice will initially try to escape before eventually giving up and 
becoming immobile. Immobility is defined as little to no movement of body or limbs, or 
the absence of a struggle to escape. Increases or decreases in immobility time are 
considered depression- or antidepressant-like, respectively. As with the FST, it is a 
reliable screen for antidepressant efficacy in humans.  
a) b) 
Figure 1.4. Tests for depression-like behaviors in mice. a, the FST 
consist of a beaker filled with temped water. The mouse is placed in the 
water and observed for swimming, climbing and immobility. Decreased 
immobility is indicative of anti-depressant-like behavior. b, For the TST, 
mice are taped to a bar and observed for immobility time. Decreased 
immobility time is indicative of anti-depressant-like behavior.  
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1.5.3 Tests for learning and memory in mice 
As with tests of anxiety and depression, tests of memory in mice often focus on 
one general aspect of memory, such as “spatial” memory or “object” memory. However, 
the parameters of any single memory test can often be manipulated to analyze 
numerous aspects of this memory domain, such as increasing or decreasing the inter-
trial intervals during training to assess acquisition, or the interval from training to testing 
to assess short- vs long-term memory. Additionally, when a drug manipulation is 
involved, treatment can be 
given at any stage ranging 
from prior to training to prior to 
testing, in order to manipulate 
acquisition, consolidation, or 
recall.  
The object recognition 
test (ORT) is a relatively quick 
and efficient test of learning 
and memory that can be easily 
altered to assess different 
aspects of learning and 
memory (Ennaceur and 
Delacour, 1988; Leger et al., 
2013). The ORT has quite a 
few advantages over other tests of memory, one of the more important being that it does 
Figure 1.5 Testing Parameters for the Object Recognition Test 
(ORT). a, Mice were tested over the course of three days. On day 1 
(T0), mice were placed in the open field for 5 min. On day 2 (T1), mice 
were placed in the open field with 2 identical objects and allowed to 
explore for 10 min. On day 3  (T2), mice were placed in the open field 
with one familiar object from T1 and one novel object and allowed to 
explore for 10 min. b, The following objects were used randomly as 
familiar or novel objects: small beer tasting glass, lego with duct tape, 




not require any lengthy or stressful training or reinforcement schedules. It also doesn’t 
require any form of food or water deprivation. This means that mice can be tested from a 
fairly natural baseline, absent from any unusual stressors. Additionally, the ORT exploits 
a rodent’s natural interest in exploring novelty, again negating the need for any external 
interference. Additionally, the test takes place over 2-3 days, which is much shorter than 
other common memory tests with extensive training that can take weeks or months.  
For tests of long-term memory, the ORT takes place over 3 days. Day 1 (T0) is 
merely habituation to the test chamber. Day 2 is training (T1) with 2 identical objects. 
Day 3 is 24 hr after training, and is the testing day (T2), in which the mouse is exposed 
to one of the familiar objects and one novel object (1.5a). Because mice like to explore 
novel objects over familiar ones, a mouse that “remembers” the object from T1 will spend 
a proportionally greater amount of time exploring the novel object. At 24 hr, most rodents 
show equal preference for the familiar and novel object, indicating no memory for the 
familiar object. For optimal exploration, objects used should be approximately mouse-
sized with simple, but distinct features (Fig 1.5b). Any drug that enhances memory will 
increase the preference to explore the novel object, indicating the rodent remembered 
the familiar object.  
For assessing short-term memory, a shorter delay can be used. Rodents with 
unimpaired memory should show preference for the novel object if tested 1 hr or less 
after T1. These parameters would be used when testing changes to short-term memory, 
such as with the possibility of cognitive enhancing drugs in a population of rodents that 
have genetic or chemically impaired learning and memory that are unable to remember 
the familiar object at 1 hr post T1.  
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Another commonly used test of memory, the step-through passive avoidance 
(STPA), is also fairly quick and efficient. However, this test makes use of somewhat 
more stressful testing parameters, including bright light and a shock, shifting more into 
the domain of fear memory. It was first described in 1960 by Jarvik and Essman and has 
since been used for numerous applications (Jarvik and Essman, 1960; Jarvik and Kopp, 
1967). The apparatus consists of a small dark chamber and a larger, brightly lit chamber 
connected by a guillotine door. Similar to the anxiety test mentioned above, this test 
exploits a mouse’s desire to be in a smaller, dark place over a bright open area. For 
training, mice are placed in the brightly lit chamber. When the mouse crosses into the 
dark chamber, the door is closed, and a shock is administered. This process is repeated 
until the mouse suppresses its desire to enter the dark chamber, indicating an 
association was made between the dark chamber and the inescapable shock. Testing is 
often done 24 hr after this training period and simply involves placing the mouse back 
into the brightly lit side of the chamber and measuring the amount of time until the mouse 
enters the dark side. The longer a mouse suppresses the desire to enter the dark side, 
the stronger the memory for the dark-shock association.  
The advantages of STPA are the relative quickness and simplicity of training and 
testing. As with the ORT, many of the experimental variables can be manipulated as 
necessary, including inter-trail intervals and delay to testing, as well as the shock 
duration and strength. Additionally, this test is a simple measure of stress or fear- related 
memory without having to do days or weeks of conditioning that significantly stress or 





Several members of the PDE family have shown great potential as targets for 
drug development for the treatment of numerous mood and cognitive disorders. The 
study of PDE2, specifically, has thus demonstrated a protective role of PDE2 against 
behavioral and biological changes associated with stress-induced anxiety, depression, 
and impaired learning and memory. Additionally, PDE2 inhibition has been shown to 
significantly enhance recognition memory in the ORT and similar memory tests. 
However, the research presented above has been primarily demonstrated in 
“challenged” systems, limiting our understanding of the role of PDE2 in these behaviors 
from baseline. Research into the role of PDE2 in anxiety and depression has focused on 
its protective effects from changes following both chemically and physically induced 
stress (Ding et al., 2014; Masood et al., 2009, 2008; Xu et al., 2015, 2013). Research 
into the role of PDE2 in learning and memory has made use of singly-housed rats, which 
is known to significantly alter behavior, as well as induce stress and impair memory in 
rodents (Akkerman et al., 2014b; Bianchi et al., 2006; Douglas et al., 2003; Hall, 1998; 
Lapiz et al., 2003; Thorsell et al., 2006; Weiss et al., 2004). Therefore, the main 
objective of the following studies is to understand the basic role of PDE2 in anxiety- and 
depression- like behaviors and learning and memory in mice through the following aims:  
1. Compare the effects of acute vs chronic treatment of the PDE2 inhibitor, Bay 
60-7550 on anxiety- and depression-like behaviors  
a. In order to compare the effects of acute inhibition of PDE2 vs repeated 
inhibition, which may result in more chronic neurobiological changes, 
PDE2 inhibitor Bay 60-7550 will be administered either acutely or 
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repeatedly for 14 days and mice will be tested in various tests for 
anxiety- and depression- like behavior, including the EPM, HB, FST, 
and TST.  
2. Compare the effects of peripherally vs centrally administered Bay 60-7550 on 
anxiety- and depression-like behaviors, and learning and memory.  
a. In order to parse the potential role/interference of peripherally 
expressed PDE2 on tests of mood and cognition, mice will be given Bay 
60-7550 either peripherally via IP injection or centrally via injection into 
the lateral ventricles and tested for anxiety-like behavior in the EPM, 
depression-like behavior in the TST, and effects on learning and 
memory in the STPA and ORT.  
3. Asses the role of PDE2 in learning and memory using the ORT 
a. In order to develop a more thorough understanding of the role of PDE2 
in different phases of learning and memory, PDE2 inhibitor Bay 60-7550 
will be administered during the ORT. Bay 60-7550 will be given 30-120 
min prior to training to assess the role of PDE2 inhibition in memory 
acquisition, immediately after training, and up to 3 hrs after training, to 
assess its role in memory consolidation, as well as 30 min prior to 
testing, to assess its role in memory recall 
b. In order to understand the molecular pathways that underlie PDE2-
mediated memory consolidation enhancement, various inhibitors of the 
cAMP/cGMP pathways will be administered prior to PDE2 inhibitor 
administration, in an attempt to block the memory-enhancing effects of 
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either Bay 60-7550 or ND7001. This includes inhibitors to nitric oxide 
synthase (NOS), soluble guanylyl cyclase (sGC), protein kinase G 
(PKG) and protein kinase A (PKA).  
Our central hypothesis in these studies is that PDE2 inhibition, acutely and 
chronically, peripherally and centrally, will result in anxiolytic-like and antidepressant-like 




Effects of Phosphodiesterase-2 
Inhibition on Depression- and 




 Mood disorders represent a large and growing mental health concern not only in 
the United States, but also around the world. Anxiety and depression are two of the 
most prominent mood disorders, with anxiety affecting approximately 18% of American 
adults in a given year, and a lifetime prevalence of 28.8%, and depression affecting 
approximately 7% of American adults in a given year, with a lifetime prevalence of 
approximately 17% (Kessler et al., 2005; Norquist, 1998; Services, 2009). While 
depression and anxiety are frequently found to be comorbid (50-70% lifetime 
comorbidity), symptoms of each of these diseases can vary widely, making successful 
treatment often difficult for physicians (Hettema, 2008).  Although a number of 
pharmacological treatment options are available, successful treatment of anxiety and/or 
depression remains limited due to suboptimal or delayed efficacy, side effects, and 
toxicity in certain populations. Additionally, though individual symptoms often vary 
widely within and between these mood disorders, the same classes of drugs, all with 
similar mechanisms, are the main pharmacologic treatment option for either diagnosis, 
regardless of the individual symptomology. Moreover, this first line treatment, the 
antidepressants, cause a number of undesirable side effects, and require continued 
treatment for many weeks in order to ease symptoms (Hirschfeld, 2000). These 
limitations reveal the great need that exists for the development of novel, more 
efficacious antidepressants and anxiolytics.  
 One of the limiting factors for the development of novel antidepressants and 
anxiolytics is our insufficient understanding of the etiology and underlying mechanisms 
of these disorders. The current generation of antidepressants, which are considered 
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first-line treatments for both anxiety and depression, primarily target the serotonergic 
and noradrenergic systems. These drugs work via inhibition of the respective reuptake 
transporter, thereby increasing the concentration and duration of serotonin and/or 
norepinephrine signaling within the synapse. While this molecular effect is seen 
immediately, a therapeutic effect may take weeks to manifest (Hirschfeld, 2000). 
Therefore, researchers are interested in identifying other potential mechanisms within 
similar brain regions that may allow for a faster onset of symptom relief.  
The super-family of phosphodiesterases (PDEs) has over 100 splice variants 
grouped into 11 gene-related families. Such diversity allows for tight regulation of cell 
signaling through cell and/or microdomain specificity. This, in combination with their 
widespread expression in the CNS, makes them prime targets for drug development for 
the treatment of mood disorders. PDE2 is of special interest due to its high expression 
in the limbic system, which is a key brain region for emotional processing.  
PDE2 is highly expressed in the forebrain, specifically in the isocortex, entorhinal cortex, 
striatum, hippocampus, amygdala, medial habenula , basal ganglia, and the substantia 
nigra (pars compacta) (Gesellchen and Zaccolo, 2011; Stephenson et al., 2009). PDE2s 
expression in these areas suggests an important role for PDE2 in mood and emotion.  
 Following NMDA receptor activation in rat cortical and hippocampal neuronal 
cultures, PDE2 was shown to be the primary PDE for the hydrolysis of cGMP (Suvarna 
and O’Donnell, 2002), and nitric oxide-induced accumulation of cGMP in striatal cell 
culture also revealed PDE2 as the PDE responsible for cGMP hydrolysis (Wykes et al., 
2002). Early exploration of the role of PDE2 in behavior indicated a protective role of 
PDE2 in oxidative stress-induced anxiety (Masood et al., 2008). Mice that received 
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BSO, a drug that induces oxidative stress, showed increased anxiety-like behavior. 
Pretreatment with the PDE2 inhibitor Bay 60-7550 prevented the BSO-induced increase 
in anxiety-related behaviors (Masood et al., 2008). PDE2 inhibitors have also shown to 
be protective against chronic unpredictable stress (Ding et al., 2014; Masood et al., 
2009; Xu et al., 2013). Mice subjected to daily stressors are likely to develop 
anxiogenic-like behaviors. Administration of PDE2 inhibitors Bay 60-7550 and ND7001 
was shown to reverse these deficits and produce anxiolytic-like responses (Ding et al., 
2014; Masood et al., 2009; Xu et al., 2013). 
 While much has been shown regarding the protective role of PDE2 in stress-
induced changes in behavior, researchers have yet to fully uncover the basic role of 
PDE2 in anxiety and depression. Therefore, the present study investigated the effect of 
PDE2 inhibition on anxiety- and depression-like behavior in mice. First, mice were 
treated daily with Bay 60-7550 for 14 days and then tested in the forced swim test 
(FST), the tail suspension test (TST), the elevated plus maze (EPM), and the hole board 
(HB) test. This chronic treatment did not result in antidepressant- or anxiolytic-like 
behavior in any of these tests. Next, to assess any potential interference of peripherally 
expressed PDE2 on changes in anxiety- or depression- like behavior, mice were given 
Bay 60-7550 either via IP injection or directly into the brain via an ICV injection into the 
lateral ventricles. Mice treated with Bay 60-7550 via IP or ICV did not show any 
changes in anxiety or depression-like behaviors, as tested in the TST, the EPM, or the 
step-through passive avoidance (STPA) test. However, mice treated with Bay 60-7550 
both centrally and peripherally did show enhanced memory, as measured in the object 





Male ICR mice (Harlan, Indianapolis, IN, USA) weighing 25-35 g (6-8 weeks old) 
were housed 5 per cage in standard polycarbonate cages, with food and water available 
ad libitum. Mice were maintained on a 12 hr light-dark cycle (lights on at 06:00 h) with 
constant temperature (22±2 °C) and humidity (55±10 %). Animals were randomly 
assigned to experimental conditions, with each animal being used only once for each 
behavioral test to prevent habituation and crossover testing effects. All mice were 
acclimated to the testing room and handled daily for 5-7 days prior to testing. All animal 
procedures in this study were reviewed and approved by the Animal Care and Use 
Committee of West Virginia University. 
2.2.2 Drugs and Treatments 
Bay 60-7550 (Caymen Chemical, Ann Arbor, MI) was dissolved in 5% ethanol, 
10% Kolliphor (Sigma Chemicals, St. Louis, MO), 85% saline.  When given ICV, Bay 
60-7550 was dissolved in 50% DMSO. Diazepam (Med-Vet International, Mettawa, IL) 
was diluted to working concentration in saline. Rolipram (Enzo Life Sciences, 
Farmingdale, NY) was dissolved in 5% DMSO and 95% saline. All drugs were given IP, 
with the exception of Bay 60-7550, which was also administered into the lateral ventricle 
via implanted cannulae. For control treatments, mice were administered the 
corresponding drug vehicle. 
For chronic drug treatments, mice were given a daily IP injection of either Bay 
60-7550 or vehicle for a minimum of 14 days prior to the start of behavior, with 
additional daily injections through the end of behavior testing. On day 14, behavior 
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testing began with the HB test followed immediately by the EPM. On day 15, mice were 
tested in the TST. On day 16, mice were tested in the FST. Testing was done 
independent of the time of the drug injection.  
For acute IP vs ICV testing, each cohort of mice (IP or ICV) was exposed to each 
behavior test in the following order from least to most stressful: EPM, ORT, TST, STPA. 
Each test had a minimum washout period of 2 days and mice were randomly assigned 
to different treatment groups for each test. Injections were given 30 min prior to testing 
(EPM, TST) or training (ORT, STPA).  
2.2.3 Cannula Surgery and ICV Drug Treatment 
Mice were anesthetized with ketamine (100 mg/kg) and xylazine (8 mg/kg) and 
placed in a stereotaxic apparatus (Stoelting Instruments, Wood Dale, IL). A 26 gauge 
guide cannula (Plastics One, Roanoke, VA) was implanted unilaterally (AP -0.2 mm 
from Bregma, ML +1 mm from the midline, DV -2 mm from skull surface using the atlas 
of Paxinos and Franklin (Paxinos and Franklin, 2008) and secured with a single skull 
screw and cranioplastic cement.  Mice were allowed to recover for 7 days before 
testing.  
On the day of training or testing, a 33 gauge injection cannula was inserted, and 
mice were administered vehicle or Bay 60-7550 using a syringe pump (KD Scientific, 
Holliston, MA) dispensing 5 ul over 5 min. The guide cannula was left in place for at 
least one additional min to allow diffusion and to minimize backflow into the guide 
cannula. At the end of the experiment, mice were injected with dye to confirm placement 




2.2.4 Forced Swim Test 
 The forced swimming test (FST) was carried out as previously described (Ding et 
al., 2014). Briefly, mice were individually placed in glass cylinders (height: 25 cm; 
diameter: 10 cm; containing 10 cm depth of water at 24 ± 1◦C) for 6 min. The sessions 
were recorded and at a later time, the last 4 min were scored for immobility by a blind 
experimenter. A mouse was determined to be immobile when there were only small 
movements necessary to keep its head above water. A decrease in immobility time is 
considered to be an anti-depressant like behavior. 
2.2.5 Tail Suspension Test 
 The tail-suspension test (TST) for depressive behavior in mice was carried out as 
described previously (Ding et al., 2014). Mice were suspended from a stand arm by a 
1.9 cm × 15 cm with masking tape loop attached to the end of their tail, leaving the last 
1 cm of tail exposed. Mice were recorded for 6-min before returning to their home cage. 
The sessions were recorded and, at a later time, the last 4 min were scored for 
immobility time by a blind experimenter. A mouse was considered immobile when there 
was no struggle and there was little to no movement of fore or hind legs. A decrease in 
immobility time is considered to be an anti-depressant like behavior.  
2.2.6 Elevated Plus Maze 
 Behavior in the elevated plus-maze test (EPM) was assessed 
as described previously (Ding et al., 2014; Masood et al., 2008). The EPM (San Diego 
Instruments, San Diego, CA) consisted of two open arms (30 cm × 5 cm) and two 
closed arms (30 cm × 5 cm × 15 cm) that extended from a central platform (5 cm × 5 
cm). The entire maze was elevated 40 cm above the floor. Mice were placed in the 
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center platform facing an open arm and allowed to explore for 5 min. All sessions were 
recorded and later scored by a blind experimenter. During the 5-min of free exploration, 
the number of entries into and the time spent in open and closed arms were noted. An 
entry was defined as all four paws in an arm. Percent of total entries into the open arms 
and percent of total time spent in the open arms was calculated to control for 
differences in locomotor activity between mice.  Significant increases in percent entries 
and time in the open arm is considered to be decreased anxiety-like behavior.  
2.2.7 Hole Board Test 
 The hole-board (HB) test was conducted as described previously (Masood et al., 
2008). The hole-board apparatus consisted of a Perspex box (60 x 60 x 35 cm) with four 
equidistant holes, 4 cm in diameter in the floor, with a small black box underneath to 
catch any mice that crawl through the hole. Each animal was placed in the center of the 
hole-board and allowed to freely explore the apparatus for 5 min. All sessions were 
recorded and later scored by a blind experimenter. The number of head-dips and total 
time spent in head- dipping were recorded. A head dip was counted when the animal 
extended its head into the hole past the ears. Significant increases in time dipping and 
number of dips is considered to be decreased anxiety-like behavior.  
2.2.8 Step-through Passive Avoidance 
 The step-through passive avoidance (STPA) test was conducted as previously 
described. The apparatus consisted of 2 equal size chambers, 1 dark chamber with an 
electrified grid floor and 1 brightly illuminated chamber, connected by a guillotine door. 
With the guillotine door open, mice were placed in the illuminated chamber and allowed 
to freely explore. As soon as the mouse entered the dark side, the guillotine door was 
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closed and a foot shock was delivered. Mice were left in the dark chamber for 30 sec, 
and then placed back into the light chamber. This process was repeated until the mouse 
stayed in the light chamber for 300 seconds, indicated it had learned the association 
between the dark side and the shock. Twenty-four hours later, the mouse was placed 
back into the light chamber, and the latency to enter the dark side was recorded.  
2.2.9 Object Recognition Test 
Behavior in the Object Recognition Test (ORT) was assessed as previously 
described (Leger et al., 2013).On the first day, mice were acclimated to the empty, 
square open field chamber for 5 min (T0: habituation). The next day, mice were injected 
with vehicle or drug. Thirty minutes later, mice were placed in the field with 2 identical 
objects and allowed to explore for 10 min (T1: training). Twenty-four hrs later, mice were 
placed back into the open field with one familiar object (i.e., object used in T1) and one 
novel object and allowed to explore for 10 min (T2: testing). All objects used were of a 
size appropriate for exploration by mice (e.g., LEGO blocks, small glass filled with 
paper, small freezer pack) and were placed at a diagonal in the box. Objects and object 
locations were counterbalanced for novel vs familiar use and orientation in the box. All 
testing was done under low light conditions. Both T1 and T2 sessions were video 
recorded and time spent exploring the objects was later scored by an experimenter 
blinded to treatment conditions. For the testing phase, only the first 5 min of exploration 
were scored, or until the mouse reached the minimum exploration time. Mice that did 
not reach a minimum exploration time of 20 seconds during T1 or T2 were excluded 
from analysis. The discrimination index (DI) was calculated for each mouse during T2: 
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[DI = (novel object exploration time – familiar object exploration time)/(novel object 
exploration time + familiar object exploration time)].   
2.2.10 Statistical Analysis 
Data are expressed as means ± S.E.M. Comparisons among groups were first 
analyzed via one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple 




2.3.1 Repeated treatment with Bay 60-7550 did not decrease depression-like 
behavior in the forced swim test or tail suspension test. 
 Bay 60-7550, given daily for 14 days, did not result in significant changes in 
depression-like behavior. Neither dose (0.5 mg/kg or 1 mg/kg) changed immobility time 
when compared to vehicle treated mice in the FST (F (2, 26) = 2.59; ns; Fig 2.1a) or 
TST (F (2, 22) = 1.55; ns; Fig 2.1b), both screens for antidepressant-like behavior.  
Figure 2.1 Repeated treatment with Bay 60-7550 does not induce antidepressant-like behavior in the 
forced swim test (FST) or tail suspension test (TST). a, Compared to vehicle, mice treated with Bay 60-
7550 (0.5 mg/kg or 1 mg/kg) daily for 14 days did not show significantly decreased immobility time in the 
FST. b, Mice treated with Bay 60-7550 (0.5 mg/kg or 1 mg/kg) daily for 14 days did not show significantly 
decreased immobility time in the TST. Bars represent means ± S.E.M. n=8-10 mice/group 
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2.3.2 Repeated treatment with Bay 60-7550 did not decrease anxiety-like behavior 
in the elevated plus maze or hole board test 
Bay 60-7550, given daily for 14 days, did not result in significant changes in 
anxiety-like behavior. Neither dose (0.5 mg/kg or 1 mg/kg) changed the number of dips 
(F (2, 24) = 0.70; ns; Fig 2.2a) nor time dipping (F (2, 24) = 0.18; ns; Fig 2.2b) in the HB 
test, when compared to vehicle treated mice. Additionally, neither dose (0.5 mg/kg or 1 
mg/kg) changed the percent of entries into the open arm (F (2, 26) = 0.02; ns; Fig 2.2c) 
nor the percent of time spent in the open arm (F (2, 26) = 0.08; ns; fig 2.2d), when 
compared to vehicle treated. 
Figure 2.2 Repeated treatment with Bay 60-7550 does not decrease anxiety-like behavior in the 
hole board (HB) or elevated plus maze (EPM). a, Compared to vehicle, mice treated with Bay 60-7550 
(0.5 mg/kg or 1 mg/kg) daily for 14 days did not significantly increase the number of dips, b, or time 
dipping in the HB test. c, Mice treated with Bay 60-7550 (0.5 mg/kg or 1 mg/kg) daily for 14 days did not 
increase the percent of open arm entries, d, or increase the percent time in the open arms of the EPM. 
Bars represent means ± S.E.M. n=8-10 mice/group 
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2.3.3 Neither central nor peripheral 
administration of Bay 60-7550 decreased 
depression-like behavior in the tail 
suspension test 
 No change in depression-like behavior 
was observed with either IP (peripheral 
injection) or ICV (central injection) 
administration of Bay 60-7550. A single IP 
injection of Bay 60-7550 (3 mg/kg) did not 
alter immobility time in the TST (Fig 2.3a; ns) 
A single ICV injection of Bay 60-7550 (30ug) 
30 min prior to testing did not alter immobility 
time in the TST (Fig 2.3b; ns).  
2.3.4 Neither central nor peripheral 
administration of Bay 60-7550 decreased 
anxiety-like behavior in elevated plus maze  
 No change in anxiety-like behavior was observed with either ICV or IP 
administration of Bay 60-7550.  A single IP injection (peripheral) of Bay 60-7550 (3 
mg/kg) 30 min prior to testing did not alter percent of entries into the open arms (Fig 
2.4a; ns) or percent of time spent in the open arms (Fig 2.4b; ns) when compared to 
vehicle treated mice in the EPM. A single injection of the anxiolytic diazepam (2 mg/kg) 
30 min prior to testing did significantly increase the percent of entries into the open arm 
(F (2, 33) = 4.88, p<0.01; Fig 2.4a) and percent of time spent in the open arm (F (2, 33) 
Figure 2.3 Neither peripheral nor central 
administration of Bay 60-7550 induces 
antidepressant-like behavior in the tail 
suspension test (TST). a, Compared to 
vehicle, mice treated with Bay 60-7550 (3 
mg/kg) either via IP injection or b, Mice treated 
with Bay 60-7550 (30 ug) via ICV injection did 
not show changes in immobility time in the 




= 5.71, p<0.01; Fig 2.4b). A single ICV injection (central) of Bay 60-7550 (3 mg/kg) 30 
min prior to testing did not alter percent of entries into the open arm (Fig 2.4c; ns) or 
percent of time in the open arm (Fig 2.4d; ns).  
2.3.5 Neither central nor peripheral administration of Bay 60-7550 enhanced 
memory in the step-through passive avoidance test 
 No change in the latency to enter the dark side of the test chamber (i.e., the side 
where electric footshock was delivered during training) was observed with either ICV or 
Figure 2.4 Neither peripheral nor central administration of Bay 60-7550 alters anxiety-like behavior 
in the elevated plus maze (EPM). a, Compared to vehicle, mice treated with Bay 60-7550 (3 mg/kg) via a 
peripheral, IP injection did not show changes in percent open arm entries or, b,  percent open arm time. 
Mice treated with diazepam (2 mg/kg), showed an increase in the percent entries and time in the open arm 
(a &b). c, Compared to vehicle, mice treated with Bay 60-7550 (3 mg/kg) via a central, ICV injection did not 
show changes in percent open arm entries or, b, percent open arm time. Bars represent means ± S.E.M. 
n=8-10 mice/group. **p<0.01 vs vehicle 
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IP administration of Bay 60-7550. A single IP 
injection of Bay 60-7550 (3 mg/kg) 30 min 
prior to training did not alter the latency to 
enter the dark chamber (Fig 2.5a; ns). While a 
single injection of rolipram (1 mg/kg) 30 min 
prior to testing did significantly increase the 
latency to enter the dark side (F (2, 35) = 
3.66, p<0.05; Fig 2.5b), a single IP injection of 
Bay 60-7550 30 min prior to testing did not 
alter the latency to enter the dark side (Fig 
2.5b; ns). 
2.3.6 Central and peripheral administration 
of Bay 60-7550 enhanced memory in the 
object recognition test.  
 Both ICV and IP administration of Bay 
60-7550 resulted in significant enhancement of memory in the ORT. A single IP 
injection of either rolipram (1 mg/kg; p<0.01; Fig 2.6a) or Bay 60-7550 (3 mg/kg; p<0.01; 
Fig 2.6a) given 30 min prior to training significantly enhanced ORT memory when tested 
24 hr later (F (2, 39) = 7.633; p=0.001). A single IP injection of Bay 60-7550 (30 ug) 30 
min prior to training significantly enhanced memory in the ORT when tested 24 hr later, 
as compared to vehicle treated mice (F (2, 39) = 7.63, Fig 2.6b). 
Figure 2.5 Neither peripheral nor central 
administration of Bay 60-7550 increased 
the latency to enter the dark side in the 
STPA. a, Compared to vehicle, mice treated 
with Bay 60-7550 (3 mg/kg) either via IP 
injection or b, Mice treated with Bay 60-7550 
(30 ug) via ICV injection did not show changes 
latency to enter the dark side. Rolipram (1 
mg/kg) did increase the latency to enter the 
dark side (a). Bars represent means ± S.E.M. 




 The PDE2 inhibitor Bay 60-7550, when administered repeatedly for 14 days or 
when administered acutely via IP or ICV injection did not significantly alter depression- 
or anxiety-like behaviors. Mice treated with Bay 60-7550 (0.5 or 1 mg/kg) daily for 14 
days did not show changes in immobility time in either the FST or the TST, nor did mice 
show increased time or entries into the open arm of the EPM, or increases in time 
dipping or number of dips in the HB test.  
In order to assess any potential interference of peripherally expressed PDE2 vs 
PDE2 in the CNS, mice were given a single injection of Bay 60-7550 either via IP 
(peripheral administration) or ICV (central administration). Mice treated with Bay 60-
7550 either IP or ICV (3 mg/kg and 30 ug, respectively) did not show changes in 
immobility time in the TST or changes in open arm time/entries in the EPM. Additionally, 
neither IP nor ICV administration of Bay 60-7550 (3 mg/kg and 30 ug, respectively) 
altered the latency to enter the dark side in the STPA. However, both IP and ICV 
administration of Bay 60-7550 significantly enhanced memory in the ORT. These results 
suggest that PDE2 inhibition does not significantly mediate antidepressant- or 
Figure 2.6 Both peripheral and central administration of Bay 60-7550 enhanced memory in the ORT. a, 
Compared to vehicle, mice treated with Bay 60-7550 (3 mg/kg) either via IP injection or b, Mice treated with 
Bay 60-7550 (30 ug) via ICV injection 30 min prior to training showed enhanced memory in the ORT. 
Rolipram (1 mg/kg) also increased memory in the ORT (a). Bars represent means ± S.E.M. n=10-14 
mice/group. *p<0.05, **p<0.01 vs vehicle 
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anxiolytic-like behaviors in mice, regardless of the duration of treatment or route of 
administration. PDE2 inhibition does appear to enhance memory, as seen in the ORT. 
While memory was not enhanced in the STPA, the use of a stressful or fearful element, 
the foot shock, is certainly testing a different domain of memory (fear memory vs object 
memory) and therefore, may be altering the underlying molecular cascades responsible 
for mediating learning and/or memory. One explanation could be that the inclusion of a 
stressor may be shifting the brain regions responsible for learning and memory to those 
that rely less on PDE2. Alternatively, it is possible that the critical periods for PDE2 
inhibition are shifted for fear memory. Bay 60-7550 was only given 30 min prior to 
training. It is possible that PDE2 inhibition is more important during consolidation or 
recall events, rather than acquisition.  
While a few studies have previously shown Bay 60-7550 to be protective against 
stress-induced mood and cognitive changes, little has been done to investigate the 
effect of PDE2 inhibition on non-stress related anxiety and depressive behaviors in mice 
(Ding et al., 2014; Masood et al., 2009, 2008; Xu et al., 2015, 2011). Early studies 
showed that Bay 60-7550 was protective against increases in anxiety from chemically 
induced oxidative stress (Masood et al., 2008). Additionally, Bay 60-7550 protected 
against physical stress-induced anxiety- and depression-like effects, including daily 
restraint stress and chronic unpredictable stress (Ding et al., 2014; Xu et al., 2013). 
These studies also provided evidence that the behavioral and neuronal changes seen 
were mediated via cGMP/PKG pathway. They were able to block the protective effects 




Based on these previous findings, it was hypothesized that PDE2 inhibition would 
lead to antidepressant- and anxiolytic-like effects in non-stressed mice. The FST and 
TST are reliable screens for antidepressant-like efficacy. Drugs that are known to have 
antidepressant properties in humans significantly increase immobility time in both of 
these tests. The EPM and HB are reliable screens for anxiolytic efficacy, also with high 
predictive validity. Drugs that have anxiolytic properties increase the entries/time spent 
in the open arm of the EPM and increase the number of dips and time dipping in the HB 
test. However, no significant change in behavior was observed in any of these tests.  
From a signaling point of view, the lack of efficacy may arise from the low basal 
activity of cGMP often observed in neurons (Domek-Łopacińska and Strosznajder, 
2010; Kawamoto et al., 2013; Masood et al., 2009, 2008). While active PDE2 does bind 
and inactivate both cAMP and cGMP with similar affinity, inactive PDE2 binds cGMP 
with a much higher affinity than cAMP, and requires the binding of cGMP to induce 
positive cooperativity. Therefore, if the concentration of cGMP is low under normal 
conditions, PDE2 will likely not be activated, and, consequently, inhibition of PDE2 
would not affect cAMP signaling. On a behavioral level, this would mean that in an 
unstressed or unchallenged system, as was the case here, inhibition of PDE2 was 
ineffective due to the lack of an on switch, i.e., cGMP, for PDE2 in the first place. This 
means that stress may be altering the expression of cGMP, cAMP, or both.  
Previous research has shown that following repeated stress, either restraint 
stress or unpredictable stress, results in increases in NOS-NO levels in numerous brain 
regions, including the cortex and hippocampus (Gao et al., 2014; Harooni et al., 2009; 
Hu et al., 2012; Zhou et al., 2011). It is likely these increases in NO lead to increases in 
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cGMP levels as well (Meyerhoff et al., 1985; Southam and Garthwaite, 1993). At the 
same time, research has also showed cAMP-PKA-pCREB to be significantly decreased 
following chronic stress (Hill et al., 2012; Li et al., 2009). Though the exact mechanism 
has yet to be fully understood, when considering how a PDE2 inhibitor may be able to 
exert antidepressant/anxiolytic effects following chronic stress, but have limited to no 
efficacy in a non-stressed system, it’s important to take this cGMP/cAMP imbalance into 
consideration. Perhaps, the elevated cGMP leads to increased activation of PDE2, 
which would further decrease cAMP levels. While increasing cGMP is often associated 
with anxiety and depression (though studies are somewhat mixed), using a PDE2 
inhibitor would prevent any further degradation of cAMP levels, potentially allowing 
cAMP to accumulate and restore a balance. Alternatively, in a non-stressed system, low 
levels of cGMP and perhaps normal levels of cAMP would not afford PDE2 inhibitors 
the opportunity to have a meaningful effect.  
While the PDE2 inhibitor Bay 60-7550 did not appear to have antidepressant- or 
anxiolytic-like effects here, in terms of a clinical application, this may actually be a 
positive. Drugs that do not affect baseline behavior, but instead are protective against 
stress-induced changes in mood, may actually be preferable to an intervention that 
alters mood or cognition from baseline.  Anxiety and depression might represent, in 
part, pathologies that result from flawed mechanisms for coping with stress.  Of course, 
our understanding of the mechanism differential efficacy in stressed vs. nonstressed 
situations is limited and further research is necessary before any possible clinical 
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The following is reprinted from Lueptow, L.M., Zhan, C.-G., O’Donnell, J.M., 2015. 
Cyclic GMP-mediated memory enhancement in the object recognition test by 
inhibitors of phosphodiesterase-2 in mice. Psychopharmacology (Berl). 
doi:10.1007/s00213-015-4129-1., with kind permission from Springer Science and 
Business Media 
3.1 Introduction 
Second messenger cyclic nucleotides, 3’5’-cyclic adenosine monophosphate 
(cAMP) and 3’5’-cyclic guanosine monophosphate (cGMP), are important mediators of 
learning and memory in a variety of species (Beavo and Brunton, 2002; Bollen et al., 
2014; Bourtchuladze et al., 1994; Castellucci et al., 1980; Greengard, 1976). They are 
expressed throughout the brain and involved in the propagation of numerous signaling 
cascades, and therefore, require tight regulation (Beavo and Brunton, 2002). One 
mechanism for this is the off switch, i.e., the cyclic nucleotide phosphodiesterase- 
(PDE) catalyzed hydrolysis of the cyclic nucleotide 3’-phosphodiester bond resulting in 
the inactive 5’-monophosphate forms. As a superfamily of 11 different PDEs, with over 
100 splice variants differentially expressed throughout the brain, these enzymes are 
able to exert tight, selective control over cyclic nucleotide signaling.  
Phosphodiesterase-2 (PDE2), which catalyzes the hydrolysis of both cAMP and 
cGMP, is expressed in forebrain regions of the brain, including the cerebral cortex and 
hippocampus, regions known to be involved in learning and memory, as well as in 
peripheral organs (Stephenson et al., 2009; Van Staveren et al., 2003).  The 
expression pattern of PDE2 in the brain suggests it as a prime target for the 
 
56 
development of cognitive enhancing drugs for variety of diseases such as age-related 
cognitive decline, vascular dementia, or Alzheimer’s disease.  
While the cellular cascades responsible for mediating each of the phases 
involved in learning and memory have yet to be fully elucidated, increases in cAMP, 
cGMP, or some combination of both, are known to play roles. Activation of adenylyl 
cyclase increases production of cAMP, leading to activation of cAMP-dependent 
protein kinase (PKA) and subsequent phosphorylation and activation of the 
transcription factor cAMP-response-element-binding protein (CREB), which in turn 
initiates the production of other growth factors and cytoskeletal proteins necessary for 
memory stabilization. Similarly, activation of nitric oxide synthase (NOS) increases 
production of nitric oxide (NO), which, in turn, activates soluble guanylyl cyclase (sGC) 
and increases production of cGMP. This leads to activation of cGMP-dependent 
protein kinase (PKG), which is also able to phosphorylate and activate CREB. 
Importantly, both cAMP and cGMP are effectors for NMDA receptor-mediated 
signaling, which is important in the regulation of learning and memory; PDE2 is a 
component of this signaling pathway as a regulator of cGMP (Suvarna and O’Donnell, 
2002). 
Memory-enhancing effects following increases in either cAMP or cGMP are 
time-dependent and vary depending on tasks and brain regions involved (Bernabeu et 
al., 1996; Bollen et al., 2014; Bourtchouladze et al., 1998; Lee et al., 2005; Nonaka et 
al., 2014). Inhibition of PDE2 may lead to increases in either cAMP, cGMP, or both. 
Therefore, it is important to not only understand the role of PDE2 inhibition during 
different phases of memory formation and recall, but also to develop a better 
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understanding of the underlying pathways that are involved in PDE2 inhibitor-induced 
changes in memory.  
The object recognition test (ORT) is a simple and efficient means for evaluation 
of various stages of memory (i.e., acquisition, consolidation, and recall). As compared 
to other rodent memory tests, the ORT is able to assess short- and long-term memory 
without stressful training or reinforcement conditions or a prolonged training schedule 
(Ennaceur and Delacour, 1988; Leger et al., 2013). Furthermore, the ORT assesses 
mouse memory under more natural conditions, exploiting the mouse’s innate tendency 
to explore novelty. Previous research has shown that PDE2 inhibition during early 
consolidation (i.e., 0 - 3 hrs after training) significantly enhances object memory in rats 
(Boess et al., 2004; Bollen et al., 2014; Reneerkens et al., 2013a; Rutten et al., 2009). 
However, this effect was demonstrated in rats that were socially isolated, which is 
known to result in persistent changes in behavioral and biochemical states, including 
hyper-reactivity to novel environments and altered behavioral responses to 
psychoactive drugs (Bianchi et al., 2006; Douglas et al., 2003; Hall, 1998; Lapiz et al., 
2003; van Goethem et al., 2012).   Additionally, this research has focused on early 
consolidation mechanisms and has been limited to investigation of the role of 
hippocampus, which is not considered the primary locus of memory processing in the 
ORT (Balderas et al., 2013; Bollen et al., 2014; Brown et al., 2012; Dere et al., 2007; 
Prickaerts et al., 2002; Rutten et al., 2007; Winters et al., 2008).  
The present study examined the effects of PDE2 inhibition on behavior of mice 
in the ORT, assessing the extent to which effects depend on the phase of memory, i.e., 
acquisition, consolidation, and recall.  Further, since previous work has demonstrated 
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the importance of the NOS/sGC/cGMP/PKG pathway in effects of PDE2 inhibition, the 
effects of inhibitors of this pathway on PDE2 inhibitor-mediated enhancement of 
memory were determined.  Finally, evidence for the ability of behaviorally relevant 
doses of a PDE2 inhibitor to activate relevant signaling in rhinal cortex was obtained by 
quantifying phosphorylation of CREB (Ser-133) and vasodilator-stimulated 
phosphoprotein (VASP; Ser-239).    
3.2 Materials and Methods 
3.2.1 Animals 
 Male ICR mice (Harlan, Indianapolis, IN, USA) weighing 25-35 g (6-8 weeks old) 
were housed 5 per cage in standard polycarbonate cages, with food and water 
available ad libitum. Mice were maintained on a 12 hr light-dark cycle (lights on at 
06:00 h) with constant temperature (22±2 °C) and humidity (55±10 %). Animals were 
randomly assigned to experimental conditions, with each animal being used only once 
for each behavioral test to prevent habituation and crossover testing effects. All mice 
were acclimated to the testing room and handled daily for 5-7 days prior to testing. All 
animal procedures in this study were reviewed and approved by the Animal Care and 
Use Committee of West Virginia University  
3.2.2 Drugs and Treatments 
 The PDE2 inhibitors Bay 60-7550 (Caymen Chemical, Ann Arbor, MI) and 
ND7001 (synthesized by Chang-Guo Zhan, University of Kentucky) were dissolved in 
5% ethanol, 10% Kolliphor (Sigma Chemicals, St. Louis, MO), 85% saline. Bay 60-
7550 has a Ki of about 4 nM and is 50 fold selective for PDE2 over PDE1, and 100 fold 
or more selective over other PDEs (Boess et al., 2004; Masood et al., 2009). ND7001 
has a Ki of 114 nM and is 100 fold selective for PDE2 over other PDEs (Masood et al., 
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2009). The sGC inhibitor ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one), PKA 
inhibitor H-89 (N-[2-[[3-(4-bromophenyl)-2-propen-1-yl]amino]ethyl]5-
isoquinolinesulfonamide) & PKG inhibitor KT5823 (2,3,9,10,11,12-hexahydro-10R-
methoxy-2,9-dimethyl-1-oxo-9S,12R-epoxy-1H-diindolo[1,2,3-fg:3’,2’,1’-kl]pyrrolo[3,4-
i][1,6]benzodiazocine-10-carboxylic acid, methyl ester; Caymen Chemical, Ann Arbor, 
MI) were dissolved in 25% DMSO, 75% saline. The NOS inhibitor L-NAME (N5-
[imino(nitroamino)methyl]-L-ornithine, methyl ester, monohydrochloride; Caymen 
Chemical, Ann Arbor, MI) was dissolved in saline. Drug doses were selected based on 
effective doses used previously in the literature (Almeida et al., 2006; Chien et al., 
2005; Chijiwa et al., 1990; Cunha et al., 2014; Lee et al., 2003; Wu et al., 2006; Xu et 
al., 2015, 2013). All drugs were given IP, with the exception of H-89 and KT5823, 
which were administered into the lateral ventricle via implanted cannulae. For control 
treatments, mice were administered the corresponding drug vehicle. 
3.2.3 Cannula Surgery and ICV drug administration 
 Mice were anesthetized with ketamine (100 mg/kg) and xylazine (8 mg/kg) and 
placed in a stereotaxic apparatus (Stoelting Instruments, Wood Dale, IL). A 26 gauge 
guide cannula (Plastics One, Roanoke, VA) was implanted unilaterally (AP -0.2 mm 
from Bregma, ML +1 mm from the midline, DV -2 mm from skull surface using the atlas 
of Paxinos and Franklin (Paxinos and Franklin, 2008) and secured with a single skull 
screw and cranioplastic cement.  Mice were allowed to recover for 7 days before 
testing.  
On the day of training in the ORT, a 33 gauge injection cannula was inserted, 
and mice were administered vehicle, H89 or KT5823 using a syringe pump (KD 
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Scientific, Holliston, MA) dispensing 5 ul over 5 min. The guide cannula was left in 
place for at least one additional min to allow diffusion and to minimize backflow into the 
guide cannula. At the end of the experiment, mice were injected with dye to confirm 
placement of the cannula; mice with incorrect cannula placement were excluded from 
analysis. 
3.2.4 Object Recognition Test 
 Behavior in the Object Recognition Test (ORT) was assessed as previously 
described (Ennaceur and Delacour, 1988; Leger et al., 2013). As shown in Figure 2.1a, 
mice were trained and tested over 3 days. On the first day, mice were acclimated to the 
empty, square open field chamber for 5 min (T0: habituation). The next day, mice were 
placed in the field with 2 identical objects and allowed to explore for 10 min (T1: 
training). Twenty-four hrs later, mice were placed back into the open field with one 
familiar object (i.e., object used in T1) and one novel object and allowed to explore for 
10 min (T2: testing). All objects used were of a size appropriate for exploration by mice 
(Fig 2.1b) and were placed at a diagonal in the box. Objects and object locations were 
counterbalanced for novel vs familiar use and orientation in the box. Between trials, the 
apparatus and each object was carefully cleaned with 95% ethanol to remove odor 
cues. All testing was done under low light conditions. Both T1 and T2 sessions were 
video recorded and time spent exploring the objects was later scored by an 
experimenter blinded to treatment conditions. For the testing phase, only the first 5 min 
of exploration were scored, or until the mouse reached the minimum exploration time. 
Mice that did not reach a minimum exploration time of 20 seconds during T1 or T2 
were excluded from analysis. The discrimination index (DI) was calculated for each 
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mouse during T2: [DI = (novel object exploration time – familiar object exploration 
time)/(novel object exploration time + familiar object exploration time)].  
 For dose-response analysis, individual cohorts of mice were given IP injections 
30 min prior to training (T1) and memory was tested 24 hrs later (T2). For time-course 
analysis, individual cohorts of mice were given IP injections of vehicle or Bay 60-7550 
(3 mg/kg):  30, 60, 90, 120, or 180 min before training to asses memory acquisition; 0, 
1 or 3 hrs after training to assess memory consolidation; or 30 min prior to testing to 
assess memory recall. Mice were tested 24 hrs after T1.  
For pathway inhibition studies, individual cohorts of mice were given an IP 
injection of the NOS inhibitor L-NAME (20 mg/kg), the sGC inhibitor ODQ (20 mg/kg), 
or corresponding vehicle, or an ICV injection of the PKG inhibitor KT5823 (2.5 ug), or 
the PKA inhibitor H-89 (1 ug), or corresponding vehicle, 30 min prior to injection of 
vehicle, Bay 60-7550 (3 mg/kg), or ND7001 (3 mg/kg), which were administered 
immediately after T1. Mice were tested 24 hrs after T1.  
3.2.5 Immunoblot analysis 
 Thirty minutes following an IP injection of vehicle or Bay 60-7550 (3 mg/kg), 
mice were decapitated, and brains were removed and quickly dissected on ice. Using a 
1mm coronal brain matrix (Kent Scientific, Torrington, Connecticut), the caudal most 2 
mm of cortex were cut with a razor blade. From these coronal sections, the ventral 
portion of the tissue, roughly corresponding to the rhinal cortical areas, was dissected 
out. These boundaries were based on the previous literature and on the brain atlas of 
Paxinos and Franklin (Liu et al., 2003; Paxinos and Franklin, 2008; Suzuki, 1996; van 
Groen, 2001; Wan et al., 1999). Both whole hippocampi were then removed. 
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Remaining subcortical structures were discarded and remaining cortex was used for 
analysis. Aliquots of supernatant from the hippocampus, rhinal cortex, and remaining 
cortex (70 ug/well) were separated using 4-12% NuPage gels, as previously described 
(Ding et al., 2014; Masood et al., 2008; Xu et al., 2013). Prestained protein molecular 
weight markers were run in parallel according to the specific molecular weight of the 
detected protein. Proteins from the gel were then transferred to PVDF (0.25 uM for 
pCREB & pVASP; 0.44 uM for PDE2), and incubated with primary antibodies overnight 
at 4°C. After 3 washes with PBST, blots were incubated with secondary goat and-
mouse or goat anti-rabbit antibodies (LI-COR Biosciences, Lincoln, NE) for 1 hr at 
room temperature. Bands were detected using LI-COR infrared imaging system. 
Labeled protein bands were compared within individual blots and normalized as a 
fraction of control density for analysis between blots. 
3.2.6 Statistical Analysis 
 Data are expressed as means ± S.E.M. Comparisons among groups were first 
analyzed via one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple 
comparisons tests. A p value of less than 0.05 was considered significant. For analysis 
of the effects of PDE2 inhibitors on different learning and memory phases (acquisition, 
consolidation, or recall), each phase was analyzed using two-way ANOVA followed by 
Bonferroni’s multiple comparisons tests, with the exception of recall, which only had 
one time point and was analyzed with an unpaired t-test. Group sizes varied based on 







3.3.1 Dose-dependent memory enhancement using PDE2 inhibitors 
  Both phosphodiesterase inhibitors Bay 60-7550 (F (5,81)=7.15, P<0.0001; Fig 
3.1a) and ND7001 (F (5, 75) = 2.71, p<0.05; Fig 3.1b) enhanced memory in the ORT in 
a dose-dependent manner.  When given 30 min prior to training, 0.5 mg/kg (p<0.05), 1 
mg/kg (p<0.001), 3 mg/kg (p<0.0001), and 6 mg/kg (p<0.001), but not 0.1 mg/kg, of 
Bay 60-7550 significantly enhanced memory in the ORT when tested 24 hrs after 
training (Fig 3.2a). For ND7001, 1 mg/kg (p=0.05), 3 mg/kg (p<0.05), and 6 mg/kg 
(p=0.05), but not 0.1 or 0.5, mg/kg, given 30 min prior to training significantly enhanced 
memory in the ORT (Fig 3.1b). Because the most robust effects were at 3 mg/kg for 




Figure 3.1 PDE2 inhibitors enhanced memory in the ORT. a, Bay 60-7550, when given 30 min 
prior to training, improved memory in a dose-dependent manner, as seen by an increase in the 
discrimination index (see Methods).  b, ND7001, when given 30 min prior to training, improved 
memory in a dose-dependent manner, as seen by an increase in the discrimination index. Bars 




3.3.2 PDE2 inhibition during acquisition, early consolidation, or recall 
significantly enhances memory in the ORT. 
 In order to understand the role of PDE2 at various phases of learning and 
memory, the PDE2 inhibitor Bay 60-7550 (3 mg/kg) was administered 30, 60, 90, or 
120 min prior to training (acquisition), 0, 1, or 3 hrs after training (consolidation), or 
immediately before testing (recall). 
Bay 60-7550 significantly 
enhanced memory when 
administered during acquisition 
(main effect, time of injection, F(4, 
132) = 2.50, p<0.05; main effect, 
treatment, F(1, 132) = 14.50, 
p<0.001; no interaction, time of 
injection x treatment, F(4, 132) = 
2.10, ns), early consolidation (no 
main effect, time of injection, F(2, 
83) = 1.74, ns; main effect, 
treatment, F (1, 83) = 6.22, 
p<0.05; no interaction, time of 
injection x treatment, F(2, 83) = 
2.86, ns) or recall (p<0.05). Mice 
treated with Bay 60-7550 30 min 
prior to training had significantly 
Figure 3.2 PDE2 inhibition during acquisition, early 
consolidation, or recall significantly enhanced 
memory in the ORT. a, Bay 60-7550 (3 mg/kg) 
significantly enhanced memory when given 30 min prior 
to training (acquisition). b, Bay 60-7550 (3 mg/kg) given 
immediately after training (consolidation) or 30 min prior 
to testing (recall) significantly enhanced memory, as 
seen by an increase in the discrimination index. Bars 
represent mean ± S.E.M.; n= 10-18 per group.  
 
65 
enhanced memory in the ORT (p<0.001; Fig 3.2a). Mice treated with Bay 60-7550 
immediately after training, but not 1 or 3 hrs after training, had significantly enhanced 
memory in the ORT (p<0.01, Fig 3.2b), as did mice treated with Bay 60-7550 30 min 
prior to recall testing (p<0.05; Fig 3.2b).   
3.3.3 Enhancement of memory in the ORT following PDE2 inhibition during early 
consolidation is mediated via NOS/cGMP/PKG pathway. 
 To parse the roles of the cAMP vs cGMP pathways in Bay 60-7550 and ND7001 
mediated memory enhancement during early consolidation, mice were pre-treated with 
pathway inhibitors in an attempt to block the effects of PDE2 inhibition. Each cohort of 
mice was pre-treated with one of the pathway inhibitors (or corresponding vehicle) 30 
min prior to Bay 60-7550 (3 mg/kg) or ND7001 (3 mg/kg), which were given 
immediately after training (T1). Alone, the NOS inhibitor L-NAME (20 mg/kg) had no 
effect on memory, but blocked the effects of both Bay 60-7550 and ND7001 (F (5, 68) 
= 10.09, P < 0.0001; Fig 3.3a). The sGC inhibitor ODQ (20 mg/kg), given 30 min prior 
to Bay 60-7550, had no effect alone, but blocked the memory-enhancing effects of both 
Bay 60-7550 and ND7001 (F (5, 67) = 6.26, P < 0.0001; Fig 3.3b).  
Next, the downstream actions of the cyclic nucleotides were examined by 
assessing the roles of PKA and PKG in PDE2 inhibitor-enhanced memory in the ORT. 
Mice were administered either the PKG inhibitor KT5823 (2.5 ug) or the PKA inhibitor 
H-89 (1 ug). As compared to vehicle treated mice, KT5823 had no effect alone, but 
when given 30 min prior to Bay 60-7550 or ND7001, it significantly blocked the 
memory-enhancing effects of both PDE2 inhibitors (F (5, 74) = 5.88, P<0.001; Fig 
3.3c). By comparison, the PKA inhibitor H-89 did not block the effects of Bay 60-7550 
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(p=0.42) or ND7001 (p=0.07; Fig 3.3d) on memory in the ORT. It is important to note 
that the lack of an effect of H-89 does not rule out the possibility of a false-negative 
finding. However, the dose of H-89 used here has been shown to effectively inhibit 
Figure 3.3 Inhibitors of the NOS/sGC/cGMP/PKG pathway blocked the memory-enhancing effects 
of PDE2 inhibition in the ORT. Mice were pretreated with an inhibitor of the cAMP or cGMP pathway 
30 min prior to Bay 60-7550 (3 mg/kg) or ND7001 (3mg/kg), which were given immediately after training.  
For all panels, pre-treatment with vehicle and subsequent treatment with Bay 60-7550 or ND7001 
significantly enhanced memory, as seen by an increase in the discrimination index. a, Pretreatment with 
the NOS inhibitor L-NAME (20 mg/kg) blocked the memory-enhancing effects of both Bay 60-7550 and 
ND7001. b, Pretreatment with the sGC inhibitor ODQ (20 mg/kg) blocked the memory-enhancing effects 
of both Bay 60-7550 and ND7001 c, Administration of PKG inhibitor KT5823 (2.5 ug) into the lateral 
ventricles also blocked the memory-enhancing of both PDE inhibitors . d, Administration of PKA inhibitor 
H-89 (1 ug) into the lateral ventricles did not block the memory-enhancing effects of Bay 60-7550 or 
ND7001. n= 10-15 per group. Bars represent mean ± S.E.M. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 vs Vehicle pretreated, vehicle treated;  
#p<0.05, ##p<0.01, ###p<0.001 vs vehicle pretreated, Bay 60-7550 treated; 
 $p<0.05, $$p<0.01, $$$p<0.001 vs vehicle pretreated, ND7001 treated. 
 ns vs vehicle pretreated, Bay 60-7550 or ND7001 treated. 
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PKA in vivo in numerous previous studies (Almeida et al., 2006; Cunha et al., 2014; 
Wu et al., 2006; Xu et al., 2015, 2013). 
3.3.4 Bay 60-7550 enhanced CREB and VASP phosphorylation 
 Both PKA and PKG phosphorylate and activate the transcription factor CREB at 
Ser-133, a necessary step in activation of the transcription machinery shown to be 
involved in rodent memory. Since memory in the ORT is thought to be mediated 
primarily by the rhinal cortex and partially by the hippocampus, these regions were 
examined for changes in the phosphorylation state of CREB (pCREB) following Bay 
60-7550 administration (Fig 3.4a). Bay 60-7550 (3 mg/kg) significantly increased CREB 
phosphorylation at Ser-133 in the rhinal cortices (p<0.01; Fig 3.4b), as well as the 
cortex and hippocampus (p<0.05 for both; Fig 3.4c & d).  
Cortex 
Figure 3.4 Bay 60-7550 significantly enhanced phosphorylation of CREB at Ser-133. Mice were 
treated with either vehicle or Bay 60-7550 (3 mg/kg) and sacrificed 30 min later. Brains were dissected 
into rhinal cortical areas, hippocampus, and remaining cortex. a, representative blot of each of the 3 
brain regions probed. b, 3 mg/kg Bay 60-7550 significantly enhanced pCREB levels in the rhinal 
cortex, c, the remaining cortex, d, and the hippocampus. 




The NOS-cGMP-PKG pathway inhibitors, L-NAME, ODQ and KT5823, were 
able to block the memory-enhancing effects of PDE2 inhibition during early 
consolidation, suggesting that these effects are mediated via this pathway. To test the 
activity of PKG specifically, changes in phosphorylation of VASP, a target of PKG at 
Ser-239, were probed in all three brain regions (Fig 3.5a).  The standard dose of Bay 
60-7550 (3 mg/kg) increased pVASP in the rhinal cortex (p<0.001; Fig 3.5b), the 
remaining cortex (p<0.05; Fig 3.5c), and the hippocampus (p<0.01; Fig 3.5d).    
2.4 Discussion  
The PDE2 inhibitors Bay 60-7550 and ND7001, when administered 30 min prior 
to training, enhanced memory in the ORT in a dose-dependent manner in mice.  Bay 
Cortex 
Figure 3.5 Bay 60-7550 significantly enhanced phosphorylation of VASP at Ser-239. Mice were 
treated with either vehicle or Bay 60-7550 (3 mg/kg) and sacrificed 30 min later. Brains were dissected 
into rhinal cortical areas, hippocampus, and remaining cortex. a, representative blot of each of the 3 
brain regions. b, 3 mg/kg of Bay 60-7550 significantly enhanced pVASP levels in the rhinal cortex, c, the 
remaining cortex, d, and the hippocampus. *p<0.05, **p<0.01, ***p<0.001 vs vehicle 
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60-7550 also enhanced memory when administered immediately after training or prior 
to recall testing.  This suggests that PDE2 is involved in signaling pathways that 
regulate memory during its acquisition, early consolidation, and recall.  The early 
consolidation effects of PDE2 inhibition appear to be mediated via the NO/cGMP/PKG 
signaling cascade, since they were blocked by inhibitors of NOS, sGC, and PKG. We 
were able to confirm these findings with a second PDE2 inhibitor, ND7001, whose 
memory-enhancing effects were also blocked by inhibitors of the NO/cGMP/PKG 
pathway. These results are consistent with the current literature, which has shown 
similar effects of Bay 60-7550 during early consolidation (i.e., immediately after 
training) in the ORT in rats (Boess et al., 2004; Domek-Łopacińska and Strosznajder, 
2008; Reneerkens et al., 2013a; Rutten et al., 2009, 2007; van Donkelaar et al., 2008).  
Additionally, we found that the PDE2 inhibitor Bay 60-7550 increased the 
phosphorylation of the transcription factor CREB at Ser-133 and VASP at Ser-239, 
both targets of PKG (Carlezon et al., 2005; Johannessen and Moens, 2007). While this 
does not preclude a role for cAMP/PKA in PDE2 inhibitor-enhanced learning and 
memory for the ORT, due to the fact that both PKA and PKG are able to phosphorylate 
CREB at Ser-133, the ability of Bay 60-7550 to enhance phosphorylation of VASP at 
Ser-239 indicates that behaviorally relevant doses of Bay 60-7550 increase cGMP 
signaling in relevant brain regions.   
 Using mice, we have replicated and extended what has previously been shown 
with Bay 60-7550 in the ORT for rats (Boess et al., 2004; Bollen et al., 2014; Domek-
Łopacińska and Strosznajder, 2008; Prickaerts et al., 2002; Rutten et al., 2007; 
Suvarna and O’Donnell, 2002; van Staveren WC et al., 2001; Xu et al., 2015). Bollen 
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and coworkers showed that injecting a PKG inhibitor directly into CA1 of the 
hippocampus blocked the memory-enhancing effects of Bay 60-7550, while a PKA 
inhibitor did not (Bollen et al., 2014). We were able to replicate this with not only a PKG 
inhibitor, but also inhibitors of NOS and sGC, which are upstream of PKG; this is 
consistent with NOS/sGC/PKG mediation of anxiolytic effects of these PDE2 inhibitors 
(Masood et al., 2009). One major difference between our findings and previously 
published reports involves the time-course for Bay 60-7550. Rutten and coworkers 
found Bay 60-7550 to significantly enhance memory when given 0 or 3 hrs after 
training (Rutten et al., 2007). However, we found that Bay-60-7550 enhanced memory 
when given up to 30 min prior to training, immediately after training, and 30 min prior to 
recall, but not 3 hrs after training. At present, the reason for this difference is unknown, 
but may indicate a species difference or be due to methodological differences 
discussed below.   
While our findings in mice largely agree with the previous literature, it is 
important to note critical methodological differences between previously published work 
regarding PDE2 and enhanced memory in the ORT and the present study. First, 
because published protocols for the ORT vary greatly, we have adapted our protocol 
from Leger and coworkers, who carefully analyzed a number of different parameters for 
the use of ORT in mice, including frequency and duration of habituation, training and 
testing, as well as the length of the inter-trial interval, inclusion criteria, and also object 
characteristics and other environmental conditions (Leger et al., 2013). Based on their 
optimization of experimental conditions, mice in the present study only received one 
habituation exposure (5 min) and one training exposure (10 min). We also set a 
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minimum criterion of 20 seconds of exploration for both training and testing. Following 
this protocol, we are able to reduce the number of animals needed per group without 
loss of power or significance, as compared to the previously published work. 
Additionally, in contrast to previously published work, we have used naïve animals in a 
between-subjects design to reduce habituation to the test environment, as well as 
eliminate any potential crossover effect from multiple ORT exposures.  
Secondly, the bulk of the research regarding the role of PDE2 in memory in the 
ORT has been conducted in singly housed rats (Akkerman et al., 2014a; Boess et al., 
2004; Bollen et al., 2014; Domek-Łopacińska and Strosznajder, 2008; Prickaerts et al., 
2002; Reneerkens et al., 2013a; Rodefer et al., 2012; Rutten et al., 2009, 2007; van 
Donkelaar et al., 2008). While research into the effects of social isolation on rodent 
behavior has varied somewhat based on sex, strain, and duration of isolation, it has 
been shown to result in numerous behavioral, neurochemical, and neurophysiological 
changes, as well as differential responses to psychotropic drugs, and has been used 
as a model for various psychiatric disorders, including schizophrenia (Akkerman et al., 
2014b; Bianchi et al., 2006; Douglas et al., 2003; Hall, 1998; Lapiz et al., 2003; 
Thorsell et al., 2006; Weiss et al., 2004). Of particular note, social isolation in rats has 
been shown to result in a hyperactive state with increased novelty seeking and 
increases in exploration time during the ORT, which complicates the interpretation of 
both behavioral and biochemical outcomes following PDE2 inhibition in these rats 
(Bianchi et al., 2006; Douglas et al., 2003; Thorsell et al., 2006).  Additionally, social 
isolation leads to increased levels of anxiety-like behavior and results in altered 
hippocampal organization and hypothalamic-pituitary-adrenal axis function (Bianchi et 
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al., 2006; Weiss et al., 2004). These changes are important to note because PDE2 
inhibition is  protective against stress-induced anxiety- and depression-like behavior, as 
well as stress-induced deficits in learning and memory, further complicating the 
interpretation of results in socially isolated rats (Ding et al., 2014; Masood et al., 2009, 
2008; Xu et al., 2015, 2013). Also, while mice and rats are often used interchangeably 
in behavioral research, it is possible that the lack of an effect of Bay 60-7550 when 
given at 3 h may be due to differences in the consolidation windows for cAMP, as 
suggested by early work in a mouse hippocampal slice preparation by Bollen and 
colleagues (Bollen et al., 2015). 
Finally, when investigating the role of PDE2 in memory in the ORT, it is 
important to consider the expression of not only PDE2 in various brain regions, but also 
the expression of NMDA-mediated second messengers that may be involved in 
memory enhancement. Because PDE2 is able to hydrolyze and inactivate both cAMP 
and cGMP, either one or both may be responsible for enhancing memory. In primary 
rat cerebral cortical and hippocampal neuronal cultures, PDE2 is the primary PDE 
responsible for catalyzing the hydrolysis of cGMP (Zhang et al., 2002). Accordingly, 
both our research and previously published reports suggest that, for early 
consolidation, the NOS/cGMP/PKG pathway is primarily responsible for mediating the 
changes in memory that result from PDE2 inhibition (Boess et al., 2004; Bollen et al., 
2014; Masood et al., 2009; Prickaerts et al., 2002; Rutten et al., 2007; Suvarna and 
O’Donnell, 2002; van Staveren WC et al., 2001; Xu et al., 2013).  Furthermore, the 
ORT is thought to be mainly mediated via rhinal cortical areas (e.g., entorhinal, 
perirhinal, & postrhinal cortex) (Antunes and Biala, 2012; Brown et al., 2012; Dere et 
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al., 2007; Seoane et al., 2012).   When looking at the differential expression of NOS in 
the hippocampus vs rhinal cortical areas, the entorhinal, perirhinal, postrhinal cortices 
have significantly higher levels of NOS than either dorsal or ventral hippocampus (Liu 
et al., 2003). Conversely, arginase activity is significantly higher in hippocampal areas 
as compared to rhinal cortices. Because NO is synthesized by NOS from L-arginine, 
higher concentrations of arginase will result in less available L-arginine as a substrate 
for NOS. However, previous work investigating the potential underlying neural 
mechanisms for PDE2-enhanced memory in the ORT has focused on the role of the 
hippocampus, specifically, with minimal consideration for the rhinal cortical areas 
(Bollen et al., 2014; Prickaerts et al., 2002). In this study, we have taken a step back 
and addressed a more global approach, injecting the PKA and PKG inhibitors into the 
lateral ventricles for widespread inhibition, rather than focusing on a specific region. 
Futures studies involving the use of the ORT, however, should consider shifting focus 
to more rhinal cortical areas, rather than hippocampal areas. It should be noted, 
however, that the brain regions thought to mediate behavior in the ORT vary based on 
the testing parameters. The apparatus used for much of the previous work with PDE2 
and memory is reported as having distinct wall features that likely confer spatial 
information, making the task more hippocampal-dependent (Akkerman et al., 2015, 
2014a; Boess et al., 2004; Bollen et al., 2014; Prickaerts et al., 2002; Reneerkens et 
al., 2013a; Rutten et al., 2009, 2007, 2006; van Donkelaar et al., 2008) while our 




While non-specific changes in cyclic nucleotide concentrations act globally in 
terms of enhancing downstream signaling, targeting individual PDE subtypes may 
allow for a more fine-tuned approach based on the expression pattern of the PDE of 
interest, as well as the subcellular co-expression of other PDE family members and 
pre-existing cyclic nucleotide tone. Not only do individual brain regions have distinct 
combinations of PDE expression, but also, on a subcellular level, PDEs are 
differentially trafficked and likely involved in different aspects of signal modulation 
based on the subcellular compartmentalization (Beavo and Brunton, 2002; Bolger et 
al., 1994; Keravis and Lugnier, 2012; Kleppisch, 2009; Omori and Kotera, 2007). 
Adding an additional layer of complexity is the difference in expression of associated 
signaling molecules, such as differential expression of NOS in rhinal cortical areas vs 
hippocampal areas (Domek-Łopacińska and Strosznajder, 2008). Furthering the 
understanding of PDE2 on a global level, as well as within individual brain regions and 
at a molecular level, will aid future drug discovery efforts for enhancing memory and 
treating cognitive impairment associated with illnesses such as Alzheimer’s disease.  
2.5 Contributions 
Lindsay Lueptow performed all behavioral testing, surgical procedures, drug 
administrations, and immunoblot analysis. Special thanks to members of the Zhang 
and O’Donnell labs for assistance during surgeries.  Dr. James O’Donnell and Lindsay 
Lueptow were involved in the design of all experiments. Dr. Chang-Guo Zhan 
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4.1 Summary and Conclusions 
 Analysis of the effects of PDE2 inhibition on memory in the ORT revealed a 
dose-dependent relationship between both Bay 60-7550 and ND7001 with enhanced 
memory. Time-course assessment showed Bay 60-7550 enhanced memory when given 
30 min prior to training, immediately after training, or 30 min prior to recall, indicating 
PDE2 inhibition affects memory during acquisition, early consolidation and recall. Using 
pathway inhibitors of cAMP and cGMP to block the effects of Bay 60-7550 or ND7001 
revealed NOS/sGC/cGMP/PKG pathway primarily mediates PDE2-inhibitor enhanced 
memory. Immunoblot analysis revealed increases in pCREB at Ser133 and pVASP at 
Ser239, both downstream of PKG, further indicating a role of the cGMP pathway in 
PDE2-inhibitor mediated memory enhancement (Lueptow et al., 2015). However, PDE2 
did not appear to play a significant role in anxiety- or depression-like behavior in non-
stressed mice. Neither acute nor repeated treatment with the PDE2 inhibitor Bay 60-
7550 altered behavior in the EPM, HB, FST or TST. Additionally, route of administration 
was not a factor since neither centrally or peripherally administered Bay 60-7550 altered 
behavior in the EPM, TST, or STPA. However, peripheral and central Bay 60-7550 
significantly enhanced memory in the ORT.  .   
 Previous research has focused on the role of PDE2 in various stressed systems, 
including chemically-induced stress, restraint stress, chronic unpredictable stress, and 
singly-housed rats (Boess et al., 2004; Bollen et al., 2014; Ding et al., 2014; Domek-
Łopacińska and Strosznajder, 2008; Masood et al., 2009, 2008; Redrobe et al., 2014; 
Reneerkens et al., 2013a; Rodefer et al., 2012; Rutten et al., 2009; Sierksma et al., 
2012; van Donkelaar et al., 2008; Xu et al., 2015, 2013). In a non-stressed system, the 
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role of PDE2 is less clear. As shown previously in singly-housed rats, the current 
findings confirm PDE2 inhibition does play a significant role in learning and memory in 
non-stressed mice. However, these results do not suggest a role for PDE2 in baseline 
anxiety- or depression-like behaviors. Only one study has been published suggesting a 
role of PDE2 in anxiety-like behaviors in non-stressed mice, using the EPM and HB 
(Masood et al., 2009). The reason for the discrepancy is unknown and therefore 
requires further analysis and replication.  
4.2 Future Directions 
While the present studies certainly extend the current understanding PDE2 in 
mood and cognitive disorders, much more needs to be done to fully understand the role 
of PDE2 in rodent behavior. While the attempts to replicate the role of PDE2 inhibition in 
non-stressed mice in regards to anxiety and depression was not successful, PDE2 
inhibition significantly and repeatedly enhanced memory in the object recognition test 
(Lueptow et al., 2015). These studies laid the groundwork for delving more deeply into 
the underlying mechanisms of learning and memory in the object recognition test, 
specifically in regards to the role of PDE2 in these processes. Time-course analysis 
revealed PDE2 inhibition to be important during acquisition, early consolidation, and 
recall. While the pathway analysis indicated the NOS/cGMP/PKG pathway was 
important for mediating PDE2-inhibitor enhanced memory during early consolidation 
(when Bay 60-7550 or ND7001 were given immediately after training), the other time-
points need to be investigated further. As Bollen and coworkers showed in rats, 
cGMP/PKG was important for mediating the effects of PDE2 inhibition and memory in 
early consolidation (immediately after training) but not at later consolidation (3 hrs after 
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training); instead, PKA/cAMP appeared to be more important at the later consolidation 
time point (Bollen et al., 2014). Using the set-up described here, the same analysis 
needs to be extended to the other time-points that were found to be significant in this 
study (e.g., acquisition and recall).  
Additionally, while the Prickaerts group found PDE2 inhibition to play a role 
during early and later consolidation (0 and 3 hrs after training), here we showed PDE2 
inhibition is only important immediately after training, but not at 3 hrs (Lueptow et al., 
2015; Rutten et al., 2007).  While this is likely due to methodological or species related 
differences (see chapter 3 discussion), it is also possible that the critical periods for 
cAMP vs cGMP consolidation differ between mice and rats. Therefore, future studies 
using our methods should also include additional time-points, both between 1 and 3 hrs 
after training, as well as beyond 3 hrs after training, to fully elucidate the potential time-
course differences between the mouse and what has been reported in the rat. From 
there, pathway analysis using various pathway inhibitors can be done, similar to what 
was shown in these studies, to elucidate the precise role and timing of cAMP/PKA vs 
cGMP/PKG pathways.  
Furthermore, the bulk of research on PDE2 inhibition in mood and cognition has 
been carried out at the behavioral level. Some biochemical analysis has shown changes 
in various downstream targets of PDE2, including pCREB and pVASP (Lueptow et al., 
2015). However, once again, this was only at one time point (30 min post Bay 60-7550 
administration) with only one inhibitor at one dose (3 mg/kg). Additional time points, 
doses, and inhibitors, including ND7001 should be used to verify these results. Pathway 
inhibitors should also be used to verify the role of NOS/cGMP/PKG over cAMP/PKA, as 
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seen in the behavioral assay. Additional targets may also be investigated, including 
changes in known downstream targets of CREB, such as BDNF, which has been 
positively correlated with learning and memory (Carlezon et al., 2005; Mayr and 
Montminy, 2001). Other molecules known to target and phosphorylate CREB should 
also be tested, including the mitogen-activated protein kinase (MAPK) ERK 1 & 2, which 
has been shown to be altered following corticosterone-induced cellular stress (Xu et al., 
2013).  
While focusing on one test of memory allows for a thorough development of an 
understanding of the role of PDE2 in learning and memory, additional domains of 
memory need to be explored. Object recognition memory is an aspect of declarative 
memory, and serves as an excellent test of such memory in rodents for the potential 
translation to humans. However, it is, of course, only testing one aspect of memory. 
Future studies should work to replicate precisely what has been done (and what is to be 
done) in the ORT using other test of memory. A simple variation of ORT is the object 
location test (OLT), which uses the same set-up and parameters as the ORT, but 
instead of introducing a novel object, one of the objects is moved to a new location in 
the box, shifting the task to spatial memory. Other tests for spatial memory include the 
MWM and RAM. Because of the protective role of PDE2 in stress-induced changes in 
anxiety, depression and memory, future studies should also consider making use of 
more fear- or stress- based tests, such as the STPA or other fear conditioning tests. 
In designing future studies, researchers should consider that the role of PDE2 in 
these different memory tasks may differ, as the underlying brain regions and molecular 
cascades involved may differ. It has already been suggested that making the ORT 
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slightly more spatially-cued seems to shift the memory load from primarily rhinal regions 
to more hippocampal based regions (Akkerman et al., 2012; Brown et al., 2012; Dere et 
al., 2007; van Goethem et al., 2012; Wan et al., 1999). It is also possible that this may 
be shifting the critical periods for cAMP vs cGMP. This may also explain some of the 
differences seen between what has been reported here and what was reported by 
Bollen et al. (Bollen et al., 2014; Rutten et al., 2007). Furthermore, this may explain the 
lack of an effect following Bay 60-7550 administration 30 min prior to training in the 
STPA. Additional analysis should be done with administration of Bay 60-7550 and other 
PDE2 inhibitors at earlier time points (i.e., 1 hr prior to training)  to rule out any role in 
acquisition, as well as later time points (i.e. 0-6 hrs after training and prior to recall) to 
fully elucidate the potential of PDE2 inhibition in fear-based memory of the STPA.  
Additional behavioral analysis using a genetic system would greatly advance our 
current understanding of PDE2 in all of these behaviors. While a constitutive knockout 
of PDE2 is embryonic lethal, using more selective genetic approaches, such as Cre/Lox 
systems, would allow deletion of PDE2 in a narrower context. Global CNS knockout (but 
not peripheral PDE2 knockout) would allow for direct comparison and confirmation of 
what has been done using PDE2 inhibitors. Even more selective, brain-region specific 
approaches using viral-vector knockdowns would allow for neuro-anatomical analysis of 
where and when PDE2 is important in all of these behaviors.  
Finally, though much of what has been shown here significantly contributes to the 
current understanding of PDE2 in anxiety, depression, and learning and memory, much 
more research is needed to come to a full understanding of PDE2, its role in mood and 
cognition, and the underlying mechanisms involved. Currently, PDE2 holds great 
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potential as a novel therapeutic for the treatment of mood and cognitive disorders, and 
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